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Abstract 
Objective: To determine which socio-demographic, exposure, morbidity and symptom 
variables are associated with health-related quality of life among former and current 
heavy smokers. 
 
Methods: Cross sectional data from 2537 participants were studied. All participants 
were at ≥2% risk of developing lung cancer within 6 years. Linear and logistic regression 
models utilizing a multivariable fractional polynomial selection process identified 
variables associated with health-related quality of life, measured by the EQ-5D. 
 
Results: Upstream and downstream associations between smoking cessation and 
higher health-related quality of life were evident. Significant upstream associations, such 
as education level and current working status and were explained by the addition of 
morbidities and symptoms to regression models. Having arthritis, decreased forced 
expiratory volume in one second, fatigue, poor appetite or dyspnea were most highly 
and commonly associated with decreased HRQoL. 
 
Discussion: Upstream factors such as educational attainment, employment status and 
smoking cessation should be targeted to prevent decreased health-related quality of life. 
Practitioners should focus treatment on downstream factors, especially symptoms, to 
improve health-related quality of life. 
 
 
Keywords: Health-related quality of life (HRQoL), smoking, visual analog scale (VAS), 
EuroQol 5 Dimension (EQ-5D), multivariable fractional polynomial (MFP) 
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Chapter 1: Introduction 
1.1 What are quality of life and health-related quality of life? 
Quality of Life (QoL) is a patient- or person- reported outcome measure of 
general well-being which focuses on an individual’s own feelings and perceptions of 
present life circumstances.1 However, there is no consensus between experts as to the 
exact list of factors, or “domains”, which compose an individual’s QoL.1-5 Health-related 
quality of life (HRQoL) refers to the aspects of QoL which are affected by an individual’s 
health. In spite of the broad definitions, researchers believe that individuals are familiar 
with the terms “quality of life” and “health-related quality of life”.1-4  
The domains of HRQoL can be analyzed specifically, or on a global level as a 
measure of an individual’s overall health. Individually or globally, these domains can also 
be compared in groups of individuals with a specific disease. HRQoL research is useful 
in predicting disease symptoms and severity, survival time, medical decision-making of 
doctors and patients, compliance and evaluation of treatment, as well as cost-
effectiveness analysis. This analytic versatility makes HRQoL an extremely useful and 
important outcome measure.1-5 
1.2 Prevalence and effects of smoking on health and health-related quality of life 
In 2010, approximately 17% (20% male, 14% female) of the Canadian population 
aged 15 years and older were current smokers and 26% were former smokers.6-8 By the 
year 2025 there is expected to be over 1.6 billion smokers worldwide.9 Tobacco use is 
the single most preventable cause of illness in North America, harming several organs 
and causing multiple chronic diseases including several cancers.10,11 Multiple 
investigations conclude that smoking has a negative effect on domain specific and 
overall HRQoL.12-21 While these studies have produced useful findings, several 
investigations have not included measures of morbidities, pulmonary function or 
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symptoms. Identifying factors contributing to poor HRQoL among former and current 
smokers would allow physicians and other healthcare workers to prioritize and tailor 
treatments which maximize HRQoL of those suffering from the adverse effects of 
smoking. 
1.3 Measuring HRQoL 
This investigation utilizes the EuroQol Visual Analog Scale (EQ-VAS) and the 
EuroQol 5 Dimensional 3 Level questionnaire (EQ-5D-3L), collectively referred to as the 
EQ-5D, to measure HRQoL.22 The EQ-5D is a quick and straightforward test, designed 
for use in postal surveys, clinics and face-to-face interviews for clinical and economic 
investigations.3,23 The EQ-VAS, is a vertical scale ranging in value from 0 at the bottom 
representing “worst imaginable health state” to 100 at the top, representing “best 
imaginable health state”. Respondents are asked to rate their current health state on the 
scale.23 The EQ-5D-3L, or “descriptive system”, asks participants to report whether they 
experience none, some or severe problems in each of five domains; mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression. Given five dimensions and three 
possible scores for each dimension, a total of 243 combinations exist. Each combination 
represents a single health state. Domain level data can be analyzed by calculating odds 
ratios of reporting none, some or severe problems or by creating index values, ranging 
from 0 to 1, by applying standardized equations to a participant’s health state.23  
1.4 Pan-Canadian Early Detection of Lung Cancer Study 
To investigate the predictors of HRQoL in a population of former and current 
smokers with a heavy smoking history, data collected by the Pan-Canadian Early 
Detection of Lung Cancer Study (PanCan) were utilized. Individuals were recruited by 
newspaper, television and mailing advertisements as well as through physician and 
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dental offices between September 2008 and December 2010. Epidemiologic data were 
collected by detailed and structured in-person interview from 2537 participants.24,25 
1.5 Gaps in the Literature 
Research examining specific factors that affect HRQoL among the general 
population of individuals with a heavy smoking history is required. Many smoking-related 
HRQoL investigations took place in clinical settings where patients are more likely to 
present with severe health consequences related to smoking. Participants of these 
studies were often diagnosed with a specific smoking-related illness or were undergoing 
a specific treatment which smoking is suspected of interfering with.26,27 Results of clinical 
studies are extremely useful to their respective study populations; however, there is a 
lack of external generalizability resulting from small sample sizes and specific inclusion 
criteria which most of the general public do not meet. 
Whether clinical or population based, investigations into the factors affecting 
HRQoL commonly utilized data from studies which did not primarily focus on 
HRQoL.14,16,28 Therefore, population, exposure, morbidity or symptom variables which 
significantly affect HRQoL, but are not included in the primary study, are excluded from 
analysis.29-31 Furthermore, several previous investigations employed regression 
techniques which did not account for non-linear functions, or controlled for non-linear 
functions using categorical cut points which groups distinct observations into a single 
category.32-37 With few studies including data from multiple variable groups and 
observing the continuous relationship between independent and dependent variables, an 
incomplete or incorrect understanding of HRQoL has been obtained. 
1.6 Study Aims and Response to Research Needs 
The PanCan enrolled 2537 current and former smokers who had a lung cancer 
risk ≥2% over 6 years. Due to their heavy smoking history, many of these study 
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participants had developed a range of health related issues that could decrease their 
HRQoL. The general aim of this study is to develop a better understanding of the risk 
factors associated with decreased HRQoL in individuals with a heavy smoking history. 
Question #1. What socio-demographic, medical history, exposure, morbidity and 
symptom factors are associated with overall HRQoL as measured by the EQ VAS 
in individuals with a heavy smoking history? 
Question #2.  What socio-demographic, medical history, exposure, morbidity and 
symptom factors are associated with HRQoL domains (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression) as measured by the EQ-5D? 
Researching factors that are associated with low HRQoL may help individuals and 
clinicians identify factors which might be modifiable, preventing reductions in HRQoL 
and leading to steps which may improve HRQoL through behavioural changes or 
treatment. Additionally, it is possible that knowledge of smoking associated-decline in 
HRQoL may be used to motivate current smokers to partake in smoking cessation 
programs and quit smoking. 
1.7 Summary 
Research incorporating data from socio-demographic, medical history, exposure, 
morbidity and symptom variables among large population-based samples is lacking. 
Linear and logistic regression models utilizing a multivariable fractional polynomial 
selection procedure identified significant independent predictors of HRQoL. Discovery of 
alterable factors associated with HRQoL identified priorities for preventions, 
interventions, or treatments to help optimize HRQoL. 
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Chapter 2: Review of Literature 
2.0 Overview 
 This chapter reviews information required to understand the study rationale, 
beginning by defining and describing quality of life (QoL) and health-related quality of life 
(HRQoL). Tobacco related topics are then discussed, including prevalence of use, 
properties of tobacco smoke, health implications and previous research related to 
HRQoL. Chapter two concludes by stating the research needs this project addresses. 
2.1 What is quality of life? 
QoL is a patient, or person, reported outcome measuring general well-being by 
focusing on an individual’s own feelings and perceptions of present life circumstances.1-5 
QoL depends on various factors which often include; happiness, general health, physical 
functioning, emotional functioning, cognitive functioning, social well-being, sexual 
functioning and existential issues.1,2,5 Each of these factors is referred to as a “domain”. 
While there is no widely accepted definition of QoL or the domains composing QoL, 
experts agree that it is a construct dependent on a combination of multiple domains.1-5 
Regardless of the lack of definition, researchers believe people are familiar QoL 
and are able to decipher its general meaning.1-4 However, individuals base their QoL on 
perceptions and values of personal experiences, all of which greatly vary throughout the 
general population.2,4 For example, Quek (2005) reports age, pain, anxiety, and 
depression as significant QoL factors affecting patients with lower urinary tract infection 
symptoms.38 Whereas a study of nurses working night shifts reports duration of sleep, 
family harmony status and diet, among other factors, as contributing to overall QoL.39 
This subjectivity and variability makes creating a single concrete definition and uniform 
measurement of QoL extremely difficult.1-4,40 In order to develop accurate conclusions, it 
is essential that variables relevant to the target population are measured. 
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2.2 What is health-related quality of life? 
HRQoL focuses on the aspects of health which affect QoL.5 Even though HRQoL 
is not synonymous with QoL, the terms are often interchanged.40 Domains often 
measured in HRQoL studies include: socioeconomic status (SES), social support, or 
presence of physical risk factors and illnesses.5 By focusing on factors coinciding with 
the World Health Organization’s (1948) definition of health, “a state of complete physical, 
mental and social well-being and not merely the absence of disease” one is assured that 
measures of HRQoL, appropriately measure overall health.1-5,40, 41   
For scientific purposes, study investigators tend to define HRQoL by the items of 
the questionnaire being utilized to measure HRQoL.2 To ensure study validity, various 
HRQoL questionnaires have been created, many designed for specific demographic and 
disease groups or to assess specific domains.3 For example, the Short-Form-36 (SF-36) 
can be used to measure the health status in the general population. The European 
Organization for Research and Quality of Treatment of Cancer (EORTC) questionnaire is 
designed for use in cancer patients participating in clinical trials and also includes 
modules to be completed dependant on specific patient diagnoses. Questionnaires 
examining specific domains are often used in conjunction with other more general 
surveys to ensure that HRQoL, as a whole, is still measured.2 According to reviews of 
HRQoL questionnaires, no gold standard exists. Instrument selection should depend on 
a variety of factors including study population and research needs.42,43 
2.3 Utilizing quality of life research 
QoL research has been popular and growing since the 1970’s and is now a 
common component of clinical trials. As new treatments with varying effectiveness and 
side effects became available, focus shifted towards improving overall well-being as 
opposed to mere symptom relief.1,2,4 Studies have shown HRQoL measures have the 
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ability to predict which patients are at greater risk of developing advanced stages of 
disease as well as survival time.44-46 HRQoL also plays a significant role in shaping 
patient’s and physician’s treatment decisions, as well as cost-effectiveness analysis; 
influencing healthcare providers, insurance companies and drug agencies.1,4,47,48 By 
researching which health conditions or interventions most effect HRQoL, the balance 
between QoL, survival time and healthcare spending can be efficiently managed.1 
2.4 Researching HRQoL amongst smokers to improve care 
Several research investigations conclude that smoking negatively affects 
HRQoL.12-21 Tobacco use is the most preventable cause of morbidity and mortality in 
North America.10,11 Tobacco harms nearly every bodily organ and causes multiple 
chronic diseases including cancers.10 Compared to non-users, former and current 
smokers are more likely to report work absenteeism, utilize medical services, have 
longer hospitalizations and are more likely to experience adverse reactions to wound 
care.11,49,50 Identifying factors contributing to poor HRQoL among smokers would allow 
physicians and other healthcare workers to prioritize and tailor treatments which 
maximize HRQoL of those suffering from the adverse effects of smoking. 
2.5 Prevalence of smoking and tobacco use in Canada and globally 
In 2014, approximately 18% (21.4% male, 14.8% female) of the Canadian 
population aged 12 years and older reported being a current smoker.51 Approximately 
74% reported smoking daily, averaging 13.9 cigarettes per day.52 Cigarettes are the 
most common form of tobacco use.10 However, 4% of Canadians have smoked a form of 
cigar within 30 days, and less than 1% report using smokeless tobacco products in the 
past 30 days.7,10 As of 2012, 28% of the Canadian population aged 15 and over were 
former smokers.52 Since the PanCan recruitment dates, September 2008 to December 
2010, Canadian smoking prevalence appears to generally be declining (Figure 1).53 
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Figure 1. Percentage of smokers, Canadian population aged ≥12 by gender, 2001 to 
2013, Canadian Community Health Survey.53 
Worldwide, among low- and middle- income countries participating in the Global 
Adult Tobacco Survey, 48.6% of males and 11.5% of females were tobacco users and 
40.7% of males and 5.0% of females were smokers.54 By the year 2025 there is 
expected to be over 1.6 billion smokers.9 Global trends indicate that the number of 
smokers is slowly declining in many industrialized countries yet overall prevalence 
remains stable or increasing among many middle- and low-income countries due to 
population growth.55,56 
2.6 Why smoke? 
Among adults who become daily smokers, 88% report first cigarette use by 18 
years of age, and 99% by 26 years of age.57 Factors contributing to young adults 
beginning and continuing to smoke are the influence of friends and siblings, and stress 
relief which is often associated with poor performance in school.58,59 Furthermore, many 
young smokers are unaware of smoking’s health implications, often downplaying the 
effects and equating them to other risky behaviours. Smoking is also often perceived to 
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be a temporary, immature behaviour that young smokers believe will pass as they age.59 
Throughout aging, continued use is primarily due to the biologically addictive properties 
of nicotine as well as the psychological associations individuals make with smoking.60 
2.8 Cigarette smoke and tar 
Over 600 chemicals are added to tobacco cigarettes. Among other purposes, 
many chemicals are added to improve taste and smell and increase addictiveness.10,61 
When lit, cigarette smoke contains between 4,000 and 7,000 chemicals.10,62,63 Of these 
chemicals, 250 have harmful effects and 69 are known carcinogens.10,64,65 Tar is the 
collection of total matter in cigarettes excluding nicotine and water. Nicotine, the 
addictive chemical in cigarettes, approximates 1.8% of a cigarette’s total weight.  
2.10 Developing an addiction 
Within 10 to 20 seconds of puffing a cigarette nicotine travels to the brain, 
reaching peak blood concentration within minutes followed by a rapid decline.10 Nicotine 
stimulates acetylcholine receptors in the brain which produces dopamine, creating a 
pleasure response. This positive reinforcement mechanism is partly responsible for the 
development of nicotine addiction.10,66 
After an individual completes smoking a cigarette, nicotine and dopamine levels 
eventually decrease, leading to withdrawal. Symptoms of withdrawal may include 
irritability, anxiety, depressed mood, restlessness, sleep disturbance, and difficulty 
concentrating. Over time, acetylcholine receptors become desensitized to nicotine 
leading to decreased dopamine production. To compensate, smokers will gradually 
increase their nicotine intake by smoking stronger cigarettes or smoking more frequently. 
Withdrawal symptoms among long-term smokers begin to appear hours after smoking, 
peak within days of last cigarette and do not subside for 2 to 4 weeks. Experiencing 
withdrawal symptoms are the main reason why prolonged smoking cessation is 
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difficult.10 Psychological, sensory and environmental cues, such as seeing someone 
smoke or smoking while drinking alcohol, can also prompt an individual to smoke. 
2.11 Health outcomes associated with cigarette smoking 
 Worldwide, tobacco use is the leading preventable cause of morbidity and 
mortality (Figure 2).56,67 Smokers are twice as likely to die prematurely and live 
approximately 10 fewer years than non-smokers.68, 69 Smoking is causally linked to three 
of the top four causes of Canadian mortality (2011); cardiovascular disease (23%), 
stroke (6%) and chronic lower respiratory disease (4%). Furthermore, the Center for 
Disease Control estimates that smoking is the primary factor in 30% of cancer 
mortalities, which is the leading cause of death in Canada and the United States.10,11,70,71  
 
Figure 2. Diseases caused by smoking and exposure to second-hand smoke.10 
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2.11.1 The effect of smoking on cardiovascular disease and stroke 
Nicotine, carbon monoxide and particulate matter increase risk of developing 
various cardiovascular diseases and stroke by elevating heart rate and lowering blood-
oxygen levels. Oxidizing chemicals, such as free radicals, contribute to inflammation, 
endothelial dysfunction, oxidation of low density lipoprotein and platelet activation. These 
processes are known to contribute to the development of cardiovascular disease. This 
leads to the thickening of arterial walls due to plaque build-up and increases blood 
viscosity. As a result, when compared to never smokers, smokers are 2 to 4 times more 
likely to die from cardiovascular disease.10,72,73 More specifically, smokers are at 
approximately 6 times greater risk of experiencing myocardial infarction, 2.7 times 
greater risk of peripheral vascular disease and 1.3 times greater risk for coronary artery 
disease.10,74-76 
2.11.2 Pulmonary symptoms, morbidities and function 
Upon inhalation, the chemicals of smoke bind together, slowly building tar along 
the trachea. As the airway narrows, oxygen inhalation and carbon dioxide exhalation are 
reduced, leading to wheezing, dyspnea, fatigue and physical activity impairment. 
Furthermore, tar build up will paralyze cilia movement, hindering their ability to remove 
toxins from the body, increasing likelihood of respiratory infection. Smokers may also 
experience phlegm secretion and coughing, the body’s natural reaction to remove toxins. 
Inhaled smoke will eventually reach and destroy the alveolar sac. In turn, oxygen 
transfer into the bloodstream is decreased and elasticity of the alveolar sac is reduced, 
further hindering physical activity and increasing likelihood of wheezing, dyspnea and 
fatigue. Damage to the alveolar sac is often permanent, resulting in long-term reduction 
of forced expiratory volume and forced vital capacity.77,78 Over time smokers may 
develop chronic obstructive pulmonary disease (COPD) which is characterized by 3 
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factors; (1) airway thickening and narrowing (bronchitis); (2) destruction of alveolar walls 
(emphysema); and (3) coughing and phlegm build up as a result of chronic mucus 
secretion.79 In its most severe cases, individuals suffering from COPD will be unable to 
perform light activity and will require oxygen tubes to breathe comfortably.80  
2.12 What are the benefits of smoking cessation? 
Smoking cessation leads to immediate and long-term improvements in physical 
health and HRQoL, even for older adults.19, 81 Immediate effects of smoking cessation 
include decreased heart rate, blood pressure, blood carbon monoxide levels and 
improved breathing. Within one year of quitting, circulation improves and lung function 
increases, coughing and shortness of breath decrease, cilia regain normal function and 
the risk of coronary heart disease is halved. Within 5 years of smoking cessation, risk of 
experiencing a stroke returns to that of a never-smoker. After 5 to 10 years, risk of 
developing various cancers is halved. After 15 years, risk of developing coronary heart 
disease (CHD) returns to that of a non-smoker.82 Quitting smoking by age 50 decreases 
mortality risk by half, and by age 30, almost completely.69 
2.13 Previous research: socio-demographic, medical history, exposure, symptom, 
morbidity and pulmonary function factors and HRQoL 
2.13.1 Socio-demographics and medical history 
Gender 
 Collecting data from a nationally representative sample (N=3,010) of south 
Australians, Wilson and colleagues (2004) investigated the differences in HRQoL 
between male and female light, moderate and heavy smokers. T-tests were used to 
compare mean SF-36 scores for 733 smokers. Females reported lower mean scores in 
the domains of physical functioning (-5.1, P<0.001), role physical (-6.7, P=0.01), vitality 
(-7.8, P<0.001), social functioning (-4.6, P=0.005), role emotional (-10.0, P<0.001) and 
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mental health (5.7, P<0.001) than males. Stratifying analysis by smoking intensity, 
especially within “heavy smokers”, revealed similar results.83 Other community-based 
investigations conducted in Korea, Taiwan, the United States and Canada report similar 
findings.84-89 Clinical studies involving participants diagnosed with HIV/AIDS, asthma, 
fibromyalgia, diabetes, and individuals undergoing coronary bypass surgery also 
agree.90-94 
Age 
 Asakawa and colleagues (2012) examine longitudinal data, collected bi-annually 
from 13,665 participants over 8 years (1996/97 – 2004/05) from the Statistics Canada 
National Population Health Survey (NPHS), with the purpose of identifying factors 
associated with HRQoL trajectories. Linear mixed-models were used to identify factors 
associated with HRQoL, measured using the Health Utility Index Mark 3 (HUI3). 
Regression models were stratified by age group (young 18 to 39; middle-aged 40 to 64; 
senior 65+) in order to identify variables significant at different life points. As a result of 
aging alone, adjusting for socio-demographics, number of chronic conditions, smoking 
and drinking status, and physical activity, HRQoL generally decreased in every 
increasing age group, especially after age 60.32 These results are similar to other large 
scale national studies conducted in England, China, the United States and Australia 
which also investigate age and HRQoL in general populations.29,95-97 
Education level 
 In a nationally representative American sample (N=3,663) aged 35 and older, 
Robert and colleagues (2009), explored differences in HRQoL between socio-economic 
subgroups. To verify consistency of findings and to allow for comparisons to other 
findings four questionnaires were used to measure HRQoL; (1) EQ-5D, (2) Short Form-6 
Dimension, (3) Health Utilities Index Mark 3 and (4) asking participants to rate their 
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health as “excellent”, “very good”, “good”, “fair” or “poor”. Multivariable weighted least 
squares regression models reveal that compared to participants with at least a four year 
college degree, those with some post-secondary schooling, a high school degree, or 
less than a high school degree all had significantly lower HRQoL on each measure 
utilized.29 These associations are weaker in the latest years of life which is similar to 
findings from Asakawa et al. (2012).32 Other general population studies examining SES 
and HRQoL completed in Sweden, Poland, Greece and Canada agree with these 
findings.88,98-100 
Employment Status 
 In a cross-sectional study exploring differences in HRQoL by working status, 
Hultman and colleagues analyzed data from 487 unemployed and 2917 employed study 
participants, aged 25 to 64, in northern Sweden. HRQoL was measured in 9 domains 
(entire life, somatic health, mental well-being, cognitive ability, social life, family life, 
activity, financial situation and meaning of life) from Hörnquist’s Quality of Life, change 
and status, assessment strategy. Unemployed participants reported lower mean HRQoL 
scores in every domain.101 According to Ross and colleagues, lower income which is 
also a measure of SES, is associated with a lower HRQoL.88 Results are similar to 
Zaninotto and colleagues who investigated HRQoL trajectories in England based on 
various socioeconomic, psychosocial and health conditions.95 
2.13.2 Exposures  
Smoking 
 Utilizing cross-sectional data from the Health Survey of England (2006) Vogl and 
colleagues explored the differences in HRQoL related to smoking status. Participants 
(N=13,241) included never smokers (46.9%), occasional smokers that have now quit 
(5.4%), ex-regular smokers (26.0%), light smokers (7.0%), moderate smokers (8.6%) 
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and heavy (5.9%) smokers. HRQoL was measured with the EQ-5D. Logistic regression 
modelling was used to calculate odds ratios of reporting some or severe problems in 
each EQ-5D dimension by smoking status, overall EQ-5D index scores were also 
calculated. Compared to never-smokers, heavy smokers reported significantly lower 
HRQoL in each EQ-5D domain. Furthermore, with the exception of ex-occasional 
smokers, all other smokers reported significantly lower mean EQ-5D index scores and 
were also more likely to experience lower HRQoL when controlling for other socio-
economic, social capital, lifestyle and biologic factors compared to never smokers.12 
Other randomized controlled trials and population studies based in England, the 
Netherlands, Finland, Spain and the United States report similar findings. 12-17,19-21 
Marijuana use and HRQoL 
Exploring gender differences in HRQoL among cannabis users in the United 
States, Lev-Ran and colleagues utilized data from 18,336 males and 24,378 females. 
The SF-12 was used to measure HRQoL. General linear models stratified by gender 
identified associations between marijuana use and HRQoL. Controlling only for age, 
male cannabis users reported significantly lower physical component summary score 
(PCS) (-0.78, P<0.0001) and mental component summary score (MCS) (-0.85, 
P<0.0001) than non-users. Female cannabis users also reported significantly lower PCS 
(-0.64, P<0.05) and MCS (-1.96, P<0.0001). When controlling for age, race/ethnicity, 
education level, household income, marital status, urbanicity and mood or anxiety 
disorders, daily cannabis use was significantly associated with reduced PCS in males (-
0.35, P<0.02) and reduced MCS in females (-1.1, P<0.0001).102 Conversely, among 
those suffering from fibromyalgia, marijuana use has been associated with increased 
HRQoL by reducing pain (P<0.001), stiffness (P<0.001), enhancing relaxation (P<0.001) 
and increasing a feeling of wellbeing (P<0.001).103 
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Alcohol use 
Kaplan and colleagues (2012) examined alcohol use patterns over a 6 year span 
to identify changes in HRQoL among adults aged ≥50 years. A total of 5,404 participants 
were included in analysis. The dependent variable, HRQoL, was measured using the 
HUI3. Persistent moderate drinkers reported the highest quality of life at baseline 
compared to other drinking patterns; persistent nonusers (-0.059, P<0.01), persistent 
former drinkers (-0.078, P<0.001), decreasing users (-0.108, P<0.001), and those with 
unstable drinking patterns; U-shaped (-0.051, P<0.01) or inverted U shaped (-0.069, 
P<0.001). Throughout follow-up, the rate of HRQoL decline was equal between all 
groups.104 Results from Kaplan and colleagues (2012) are consistent with findings from 
Byles and colleagues (2006) which utilized nationally representative data from 
Australia.105 Volk and colleagues also discovered similar findings, adding that less 
frequent (P<0.05) and frequent high-quantity drinkers (P<0.05) report lower mental 
health scores than lifetime abstainers.106 
2.13.3 Morbidities 
 The following are morbidities included in the PanCan study questionnaires 
pertaining to medical history. The morbidities discussed below are those with highest 
prevalence among study participants. Morbidities for which data were collected, but are 
not discussed here, are included in the thesis data analysis. 
Cardiovascular risk factors and diseases 
Data from 189,450 participants of the 2003 Behaviour Risk Factor Surveillance 
System were analyzed by Li and colleagues (2008) to examine the association between 
having multiple cardiovascular disease risk factors (diabetes, hypertension, 
hypercholesterolemia, BMI and smoking status) as well as cardiovascular diseases 
(myocardial infarction, angina and stroke) and HRQoL. HRQoL was measured using the 
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SF-36. Adjusting for age, gender, race/ethnicity, and education, odds ratios of 
experiencing poor or fair general health among those with and without cardiovascular 
disease were calculated. Individuals with cardiovascular disease were more likely to 
report poor or fair general health and experience ≥14 days of physical or mental illness 
or impaired activity.30 Focusing on specific cardiovascular outcomes, Stafford and 
colleagues (2012) discovered that all precursors to cardiovascular disease (diabetes, 
hypertension and obesity) as well as cardiovascular diseases (myocardial infarction, 
stroke and angina) were associated with decreased HRQoL.37 Soltoft and colleagues 
(2009) also analyzed data from the Health Survey for England to specifically compare 
the relationship between BMI and HRQoL by gender. After controlling for socio-
economic status, psychosocial well-being and diagnosed morbidities, multiple linear 
regression models stratified by gender showed that those in normal BMI range reported 
the highest EQ-5D utility scores.36,107 
Arthritis and HRQoL 
Cross-sectional data from the National Health Measurement Study was analyzed 
by Khanna and colleagues (2011) to assess HRQoL in sample of American adults with 
and without self-reported arthritis. In total, 3844 adults aged 35 to 89 years participated. 
HRQoL was measured with six HRQoL instruments. Similar to national statistics, 
approximately 31% of participants reported having arthritis. HRQoL scores were 
stratified by gender, age group and presence of arthritis. In each gender and age group, 
for every HRQoL questionnaire, those with arthritis reported significantly lower mean 
HRQoL scores.108 Conclusions made by Khanna et al. agree with other population 
studies conducted by Hill et al. (1999) in the United States, and Uhlig et al. (2007) in 
Norway, which also found HRQoL scores to be lower among those with arthritis 
compared to the general population.109,110 
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Osteoporosis and HRQoL 
In their evaluation of the Quality of Life Questionnaire of the European 
Foundation for Osteoporosis 41 (QUALEFFO 41) Ferreira and colleagues (2009) 
recruited 110 post-menopausal females with and without diagnosis of osteoporosis. To 
verify accuracy of the QUALEFFO 41 participants also completed the SF-36. It is 
important to note that low scores on the QUALEFFO 41 indicate better HRQoL whereas 
high scores on the SF-36 represent better HRQoL. Mean HRQoL scores in all 
dimensions measured by the QUALEFFO 41 and SF-36 were worst among those with 
osteoporosis compared to age-matched controls without osteoporosis.111 These results 
agree with findings reported by Adachi and colleagues (2010) who utilized data from 
57,141 post-menopausal females as well as a Dutch population study (N=3,664) 
completed by Picavet and Hoeymans (2002).31,112 
Chronic obstructive pulmonary disease 
 To determine if differences in HRQoL between former and current smokers can 
be explained by cough, phlegm, pulmonary function, or exercise capacity Heijdra and 
colleagues (2002) recruited 36 smokers, 21 ex-smokers, 19 never-smokers and 41 
COPD patients. The St. George’s Respiratory Questionnaire (SGRQ) was used to 
measure HRQoL. The SGRQ measures HRQoL on a scale from 0 to 100 with lower 
scores indicating better HRQoL. ANOVA results indicated that participants suffering from 
COPD reported the highest mean SGRQ scores compared to all other groups.113 
Allergic rhinitis, asthma and HRQoL 
 Larsson and colleagues (2007) investigated the relationship between rhinitis and 
asthma on HRQoL with data from 5,918 Swedish study participants. The SF-36 was 
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used to measure HRQoL. In both males and females, non-cases reported highest 
HRQoL followed by individuals with rhinitis and without asthma. Asthmatics with or 
without rhinitis reported the lowest HRQoL scores in every SF-36 domain.114 Similar 
findings are presented by Kalpaklioglu and Baccioglu (2008) as well as Chen and 
colleagues (2011) who researched Turkish and English populations, respectively.115,116 
2.13.4 Pulmonary function  
Utilizing data from a Norwegian general population survey (N=2,306), Voll-Aarneud 
and colleagues (2008) investigated the relationships between respiratory symptoms, 
COPD severity, pulmonary function and HRQoL. Among participants with COPD, the 
GOLD (Global initiative for chronic Obstructive Lung Disease) classification system was 
used to measure COPD severity: mild (FEV1≥80% predicted), moderate (50% to 80% 
predicted), severe (30 to 50% predicted) and very severe (FEV1<30% predicted).
33,117 
The SF-12 measured HRQoL. Linear regression modelling revealed a decrease in 
HRQoL among moderate (-3.1, P<0.05) and severe or very severe (-11.5, P<0.001) 
COPD participants, when compared to those without COPD.33 Jones and colleagues 
(2011) added to these findings, reporting a significant decrease in HRQoL (measured by 
the SGRQ, the SF-12 and the Functional Assessment of Chronic Illness Therapy - 
Fatigue) with each increasing level of COPD severity.118 
2.13.5 Symptoms  
 Voll-Aanerud and colleagues (2010) analyzed data from the European 
Community Respiratory Health Survey I and II to identify respiratory symptoms 
associated with HRQoL among those with and without COPD. HRQoL was measured 
using the SF-12. Linear regression models included data from 6,009 subjects, controlling 
for age, gender, smoking status, occupation, BMI, morbidities, and study center. 
Significant factors associated with HRQoL included wheezing, being woken up by chest 
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tightness, experiencing chronic cough and experiencing chronic phlegm production.35 In 
a separate investigation of pulmonary function and HRQOL, Voll-Aanerud et al. (2008), 
also reported an negative association between dyspnea and HRQoL (-6.4, P<0.001).33 
2.14 Overview of past research investigating factors affecting HRQoL among smokers 
Given the causal link between smoking and several acute and chronic health 
outcomes, it is not surprising that multiple studies have shown an association between 
increased smoking exposure and reduced HRQoL. Most studies examined these effects 
by comparing established never, former and current smokers or they prospectively 
followed recent quitters to view the benefits of smoking cessation. Many smoking-related 
HRQoL investigations took place in clinical settings where patients were more likely to 
present with severe smoking effects. Participants of these studies were often diagnosed 
with a specific smoking-related illness or were undergoing a specific treatment which 
smoking is suspected of interfering with. For example, Garces and colleagues (2004) 
explored the relationship between smoking status and HRQoL among individuals 
diagnosed with lung cancer whereas Das and colleagues (2007) investigated the effect 
of smoking on short-term HRQoL among patients receiving sinus surgery.26,27 According 
to a systematic review of general injured populations (studies including only those with a 
specific injury were excluded), hospitalized individuals were more likely to report lower 
HRQoL than non-hospitalized populations.119 Results of clinical studies are extremely 
useful to their respective study populations; however, there is also a lack of external 
generalizability resulting from small sample sizes and specific inclusion criteria which the 
majority of the general public do not meet. 
Whether clinical or population based, investigations of factors affecting HRQoL 
commonly utilized data from other studies which do not primarily focus on HRQoL.14,16,28  
Many ancillary studies exploring the impact of factors affecting HRQoL focused on the 
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effects of a specific variable (ie. gender), or variable group (ie. socio-economic indicators 
or cardiovascular risk factors), often excluding covariates known to affect HRQoL from 
analyses. This is also prevalent amongst ancillary studies investigating the impact of 
variables from multiple groupings as many factors unrelated to the primary study’s 
objective, but known to affect HRQoL (ie. smoking status), were not measured.29-31  
Therefore, statistical analyses controlled for a selection of socio-economic factors, 
exposures, morbidities or functional abilities directly related to the study, but few studies 
accounted for several factors related to HRQoL.83,95,120,121 Furthermore, several previous 
investigations did not attempt to identify non-linear functions between predictor variables 
and HRQoL.32-37 With few studies including data from multiple variable groups and few 
analyses identifying non-linear relationships, an incomplete understanding of HRQoL 
exists. 
This study builds on previous research by addressing the aforementioned issues.  
Ensuring strong study power, data from a large population sample of former and current 
smokers, the Pan-Canadian Early Detection of Lung Cancer Study (PanCan), 
representative of the Canadian population of smokers was used. Variation in HRQoL will 
be explained using an array of sociodemographic, medical history, exposure, symptom, 
morbidity, and pulmonary function variables. Linear and logistic regression models 
utilizing a multivariable fractional polynomial (MFP) selection procedure are used to 
explain variation in HRQoL. 
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Chapter 3: Methods 
3.0 Overview 
This chapter begins by describing the purpose of the PanCan, the primary study 
from which this project obtains its data. Following, the study design, patient recruitment, 
sample characteristics, and data collection techniques are discussed. Lastly, the 
statistical analysis strategies implemented to answer study questions are discussed. 
3.1 Pan Canadian Early Detection of Lung Cancer Study 
3.1.1 Purpose 
The goal of the PanCan was to develop a new multi-modal screening strategy 
which would lead to the early detection of lung cancer. It is expected that screening high 
risk individuals for lung cancer would be effective in earlier detection of lung cancer, 
potentially improving cost effectiveness for the Canadian health care system if 
implemented.24 Results of this study contribute to knowledge required to make an 
educated decision regarding the implementation of lung cancer screening in Canada. 
3.1.2 Participant recruitment and sample size 
 PanCan recruitment took place in eight sites across Canada; Halifax, St. John’s, 
Laval, Ottawa, Toronto, Hamilton, Calgary and Vancouver from September 2008 until 
December 2010. Participants responded to advertisements in newspapers, on television 
and through the offices of doctors and dentists. Sample size calculations estimated that 
2500 participants were needed to draw definitive conclusions between biomarkers, 
spirometry and autofluorescence bronchoscopy use, and lung cancer.  
3.1.3 Inclusion and exclusion criteria 
To apply, potential participants were instructed to call a (1–800) phone number. 
Upon calling, a research assistant at the PanCan co-ordinating centre explained the 
study and collected lung cancer risk factor data which were entered into an Excel 
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spreadsheet to compute the prospective study subject’s lung cancer risk index. The lung 
cancer risk was estimated according to a model prepared by Dr. Martin Tammemagi 
using Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial data.122,123 
The purpose of the lung cancer risk index was to determine the probability 
potential study participants had of developing lung cancer. The prediction model 
probability is based on self-reported risk factors including age, education level, BMI, 
family history of lung cancer, history of COPD, chest x-ray in last three years, smoking 
duration and pack years smoked. Individuals were invited to enroll in the study if their 
risk of developing lung cancer within 5 years was ≥2%. In addition, a participant must 
have been between 50 and 75 years old and provided consent for screening procedures. 
Potential participants were excluded if they had any medical condition such as an 
acute or chronic respiratory failure, bleeding disorder, or were unlikely to benefit from the 
screening being offered. Participants were also excluded if they were taking any oral 
anti-coagulants, had a known reaction to xylocaine, salbutamol, midazolam, and 
alfentanil, or were pregnant, unwilling to have a spiral chest computed tomography, had 
a chest CT within 2 years, were unwilling to sign consent or had been diagnosed with 
cancer (excluding non-melanomatous skin cancer, localized prostate cancer, carcinoma 
in situ of the cervix, or superficial bladder cancer) within 5 years. 
3.1.4 Data collection techniques 
In the event that a potential participant met inclusion criteria without presenting 
any exclusion criteria, he or she was registered as a study participant and administered 
four questionnaires. The first focused on multiple epidemiologic factors, including socio-
demographic factors, smoking patterns, occupational exposures, family history of cancer 
and medical data. The second and third questionnaires; the short form 12 (SF-12) and 
the EuroQol Five Dimension (EQ-5D) were used to measure HRQoL. The final 
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questionnaire, the State-Trait Anxiety Inventory, measured anxiety intensity and 
distinguished between state anxiety and trait anxiety. Following the baseline 
questionnaires, a blood sample and spirometry measurements were taken. Participants 
were not financially rewarded for study participation. 
Measuring quality of life: The European Quality of Life Scale (EQ-5D) 
This thesis utilized the EQ-5D to measure HRQoL.23 The EQ-5D consists of two 
parts. The first is the EQ-5D descriptive system, also referred to as the EQ-5D-3L 
(Figure 3). This system consists of five questions, each question targeting one specific 
dimension; mobility, self-care, usual activities, pain/discomfort and anxiety/depression. 
Each dimension has three levels of response; no problems, some problems and extreme 
problems. A total of 243 unique combinations, or “health profiles”, exist. 
Domain responses can be analyzed individually, by calculating odds ratios of 
reporting none, some or severe problems. Additionally, each health profile can also be 
transformed into a single index value ranging from 0 to 1. Transformation is completed 
by applying standardized formulas derived from the general population to respective 
health profiles. Therefore, index values are representative of the general population’s 
opinions of a particular health state rather than the study participant’s.124  
The second part of the EQ-5D-3L is the Visual Analog Scale (VAS) which 
measures HRQoL using a utility value. Unlike index values which generate a HRQoL 
score based on question responses and mathematical formulas derived from the general 
population, a utility score, such as the EQ-5D VAS, is created by asking the user to rate 
their own HRQoL by providing a single numerical value (Figure 4). Both components of 
the EQ-5D-3L were designed for use in postal surveys, clinics and face-to-face 
interviews, with various populations, and takes only a few minutes to complete.23 
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By placing a check-mark in one box in each group below, please indicate 
which statements best describe your own state of health today. 
 
Mobility 
I have no problems in walking about   
I have some problems in walking about   
I am confined to bed   
 
Self-Care 
I have no problems with self-care   
I have some problems washing or dressing myself   
I am unable to wash or dress myself   
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities   
I have some problems with performing my usual activities   
I am unable to perform my usual activities   
 
Pain/Discomfort 
I have no pain or discomfort   
I have moderate pain or discomfort   
I have extreme pain or discomfort   
 
Anxiety/Depression 
I am not anxious or depressed   
I am moderately anxious or depressed   
I am extremely anxious or depressed   
 
Figure 3. EQ-5D-3L (Canadian English version) 
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To help people say how good or bad their state of health 
is, we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your state 
of health is today. 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
Figure 4.  EuroQol Visual Analog Scale (Canadian English version) 
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EQ-5D: Validity and Reliability 
The EQ-5D has been tested in various populations and has shown itself to be a 
valid and reliable measure of HRQoL. Investigations of over 1,500 participants from the 
general Canadian population residing in Alberta, and 423 Americans both concluded that 
the EQ-5D has strong construct, convergent and discriminant validity when compared to 
the 12 item Short Form Health Survey (SF-12).125,126 Luo and colleagues (2005) used 
Spearman’s correlations to conclude the EQ-5D to have strong discriminant, convergent 
and construct validity (R>0.5) when compared to the Health Utility Index 2 and Health 
Utility Index 3.127 Kontodimopoulos et al. (2008) agreed with these findings and also 
reported that the EQ-5D’s internal consistency reliability (α=0.743) exceeded the 
accepted level of 0.70 for group level comparisons.128 In a general sample of 1,666 
Israeli participants, Horowitz and colleagues (2010) concluded that the EQ-5D-3L was a 
responsive measure of HRQoL as it could adequately distinguish individuals with varying 
levels of disease as well as individuals with disease from those without. Pearson 
interclass correlation coefficients measuring test-retest reliability were also very high for 
both the EQ-5D (R=0.85) and the VAS (R=0.87).129 Other validity and reliability 
investigations of the EQ-5D in a general Dutch population, those with COPD, asthma, 
musculoskeletal disorders, diabetes, cardiovascular disease and elderly populations 
reported similar findings.8,130-134 
Spirometry Measurements 
Spirometric measurements included in this study were Forced Expiratory Volume 
in one second (FEV1) and Forced Vital Capacity (FVC). These measurements were used 
as an estimate of lung functioning and were analyzed as a percent of predicted (% 
predicted) using standardized prediction equations.135 A flow-sensitive spirometer 
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(Presto Flash Portable Spirometer Version 1.2, Spacelab Burdick Inc., Deerfield WI) was 
utilized by trained technicians to collect these data.136 
3.1.5 Lung cancer screening and study follow-up 
Study participants were followed for 5 years. All participants were screened for 
lesions using low-dose computed tomography (LDCT) and half were also screened 
using autofluorescence bronchoscopy. If no nodules were detected, participants 
completed a follow-up questionnaire or telephone interview every 6 months and were 
required to be re-screened by LDCT one year after baseline. If nodules were detected, 
follow-up was determined by the size, shape, and growth of existing nodules. 
Information gathered throughout follow-up will not be discussed further as this 
investigation only utilizes baseline data. 
3.2 Ethical considerations 
Study investigators were responsible for clearly and thoroughly explaining all 
aspects of the PanCan (NCT00751660) as well as answering any questions potential 
participants may have had. Ethics approval was obtained from each participating study 
center, and all potential participants were given informed consent forms to sign. All data 
provided for analysis in the current study to the student, Matthew Ventresca, have been 
de-identified, so identification of individuals has not been possible. This thesis is a 
secondary data analysis and does not require ethical approval from Brock University. 
3.3 Statistical analysis 
All statistical analyses were completed using Stata version 13.137 Statistics 
describing the study population and distributions of study variables were calculated. Chi-
squared tests were used to compare frequencies for nominal and ordinal level data. All 
continuous variables were non-normally distributed and analyzed using non-parametric 
test of trend.138 Major research questions were investigated using linear and logistic 
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regression techniques with a multivariable fractional polynomial (MFP) selection 
procedure. Selection of variables included in regression analyses were based on 
previous research and PanCan availability (Table 1). 
Table 1. Variables assessed for potential inclusion in regression analyses. 
Variable category Possible factors associated with HRQoL 
Independent variables  
Socio-demographic and medical 
history 
Age, gender, race/ethnicity, education level, current work status, body 
mass index, familial cancer history 
  
Smoking, Alcohol Consumption 
& Other Exposures  
Smoking status, cigarettes smoked per day (30 days before study 
entry), cigarettes smoked per day (average throughout smoking 
period), pack years smoked, smoking duration, time since quitting 
smoking, weekly alcohol consumption, monthly marijuana use 
  
Morbidities Allergies, anemia, angina, arthritis, asthma, blood disease, COPD, 
diabetes, forced expiratory volume in one second % predicted, forced 
vital capacity, hypercholesterolemia, hypertension, kidney disease, 
liver disease, myocardial infarction, osteoporosis, peripheral vascular 
disease, pulmonary fibrosis, stroke 
  
Symptoms Dyspnea, cough, phlegm, hoarse voice, wheezing, chest pain, 
fatigued, poor appetite, weight loss 
  
Dependent variables  
Quality of Life EQ-5D VAS, EQ-5D domains (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression) 
 
Question #1. What socio-economic, medical history, exposure, symptom, 
morbidity, and pulmonary function factors are associated with HRQoL? 
A MFP selection procedure was used in conjunction with linear and logistic 
regression techniques to identify variables associated with HRQoL, measured by the EQ 
VAS and EQ-5D. Utilizing VAS response data allows for the identification of factors 
associated with HRQoL based on the opinion of the study participant, as opposed to 
index values which are often used in economic analysis and reflect opinions of the 
general population. Covariates included in regression models were selected from data 
collected by the PanCan and were based on previous research outlined in chapter 2.  
Assumptions of linear regression were evaluated. To determine if VAS scores 
and potential transformations were normally distributed, histograms and tests for 
skewness and kurtosis were examined. A plot of residuals against fitted values of VAS 
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scores was created to assess homoscedasticity. Pearson correlation coefficients were 
calculated and examined for all independent variables. According to Doormann and 
colleagues, collinearity begins to severely distort model estimations and subsequent 
prediction when Pearson’s R≥0.7.139 When correlation coefficients exceeded 0.7, the 
variable which had a weaker relationship with VAS score was excluded from regression 
modelling provided that previous literature verified omission was scientifically valid. 
The Stata command mfp: reg was utilized to complete regression analyses. The 
selection of polynomial exponents available for testing models was left at default values 
(-2, -1, 0.5, 1, 2, 3). Maximum number of cycles and degrees of freedom were kept at 
their default levels; 5 and 4, respectively. Cluster adjustment according to a participant’s 
site of study participation was applied to all multivariable regression models.140 
Continuous variables were centered to their mean and rounded to the nearest whole 
number for ease of interpretation. Mickey (1989) reports that the use of a typical P-value 
set at 0.05 may result in important variables being excluded from the regression 
model.141 Sauerbrei and colleagues (2005) also discuss the importance of this issue in 
regression with an MFP selection procedure.142 To ensure that all potential covariates 
were considered for selection into the final regression model, the cut point for entry was 
set at α=0.2 in partially adjusted regression models. Four partially adjusted regression 
models were prepared prior to each fully adjusted linear or logistic regression model, 
one per variable group (socio-demographics and medical history, exposures, morbidities 
and symptoms). Independent variables with P≤0.2 in each partially adjusted regression 
model collectively underwent the MFP selection process to determine which were 
significantly associated with VAS score when adjusting for all other factors. Statistical 
significance in the fully adjusted model was set at P≤0.05. For continuous predictors, a 
significant non-linear relationship was identified if P≤0.05 when non-linear was compared 
to linear predictors in nested models. The variation in VAS score explained by models 
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was assessed using R2 values. Monitoring changes in effect estimates, significance 
values and variable pathway position in unadjusted and adjusted models allowed for the 
identification of confounders as well as potential upstream and downstream associations 
(Figure 5). Upstream associations involve variables, distal in pathway position from 
HRQoL, which are associated with an intermediary variable which is proximal and 
associated with HRQoL. Downstream associations are typically associated with HRQoL 
after full adjustment with no intermediary associations between itself and HRQoL. 
Variables with a distal pathway position may have upstream and downstream 
associations with HRQoL, which is common among socio-demographic characteristics 
but is also possible among other variable groups. 
 
 
 
 
Figure 5. Pathway position, and upstream and downstream associations 
3.3.1 MFP selection procedure 
The traditional linear regression equation (β1X) is often suitable to modelling the 
relationship between predictor and outcome variables. However, a better non-linear fit 
Upstream associations 
Downstream associations 
Symptoms 
Morbidities 
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may be possible. The MFP selection procedure extends the linear regression equation 
(β1X) by adding an exponent and, potentially, additional polynomial terms (β1X
p1 + β1X
p2 
+ β2X
p1+ β3X
p1…).142 Model complexity is controlled by two hypothesis tests, where 
α=0.05 is typical for both. The first hypothesis test determines if an independent variable 
is significant to the regression model using up to two polynomials. The second test 
determines whether a non-linear fit is more appropriate. 
Prior to starting the MFP selection process, significance levels for model 
inclusion (α1=0.05), non-linearity testing (α2=0.05) and the maximum degrees of freedom 
must be chosen (4). The full linear model is then fitted. The visiting order for subsequent 
comparisons is determined by the respective P-value for omitting each term from the 
model, beginning with the most significant predictors. 
The MFP selection process begins. If the variable assessed is categorical, the 
joint significance of its dummy variables is tested at α1 while other predictors are 
included as adjustment terms. If the result is insignificant the variable is removed from 
regression modelling, a significant result retains the variable. For continuous predictors, 
a two term polynomial is used to describe the relationship with the dependent variable. 
Assuming the term is significant and should be added to the model, it is then compared 
to the linear fit. An insignificant test result indicates that the linear fit is preferred. 
Significant results indicate that a non-linear fit is more appropriate. A following test 
comparing a single polynomial function to the dual polynomial function is completed. An 
insignificant result indicates that the single polynomial form is preferred to the dual 
polynomial function. Remaining variables are tested until none remain. This process will 
repeat up to five times, however, with a new list of predictors excluding those found to be 
previously insignificant.142 This backwards selection process, which repeats until all 
independent variables significantly predict the dependent variable, reduces the likelihood 
for negative confounding variables to be excluded from the final regression model.143 
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Linear regression assumptions tested include; 1) linear relationship between 
continuous independent variables and the dependent variable; 2) independence of 
observations; 3) the dependent variable, VAS score, is normally distributed; 4) 
correlation of predictors; 5) reducing measurement error and 6) homoscedasticity.144,145 
It is important to note that several comparisons are being made, increasing the 
probability of identifying erroneous significant relationships.146 To ensure no significant 
associations are overlooked the significance level is not decreased, as would be done in 
a Bonferroni correction for multiple comparisons. However, bootstrap confidence 
intervals are also calculated to verify consistency of the regression model. 
3.3.2 Bootstrapping stability analysis 
The Stata command mfpboot was utilized to calculate 1000 bootstrap 
replications. Bootstrap samples were derived from the study sample and are the same 
size. Each observation was replaced after being selected. Therefore, some individuals 
were selected more than once and others not at all.147 Since it is non-parametric, no 
statistical assumptions need to be satisfied.147 Model stability was assessed by 
analyzing bootstrap inclusion frequencies (BIF). While not a hypothesis test, variables 
with a BIF≥50% are typically considered as having a P<0.05.145 
To test for interaction effects new variables were created by multiplying 
independent variables suspected of having an interaction effect together (ie. gender * 
smoking duration). All interactions tested were chosen a priori, and based on literature 
review. Tested interactions focused on the relationship between socio-demographic 
variables in combination with each other and various exposure and morbidity factors. All 
interactions were tested univariately (in the presence of both independent variables) and 
in the fully adjusted linear regression model. Likelihood ratio tests were completed to 
determine if significant interactions existed. 
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Question #2.  What socio-economic, medical history, exposure, morbidity and 
symptom variables are associated with each EQ-5D domain? 
Logistic regression models, utilizing the MFP selection procedure, were used to 
identify socio-economic, medical history, exposure, morbidity and symptom variables 
significantly associated with reporting some or severe problems for each EQ-5D domain. 
Odds ratios of experiencing some or severe problems, in comparison to no problems, 
were calculated. Ideally, ordinal logistic regression would be used since each domain 
has three outcome levels. However, due to low frequencies of individuals reporting 
severe problems, which is common in population based data sets where participants 
tend to report higher HRQoL than clinical settings, individuals experiencing some or 
severe problems were combined into a single group.23 Abreu and colleagues (2008) note 
that dichotomizing response variables, especially for HRQoL studies, may lead to loss of 
information and less appropriate or incorrect conclusions.148 Ordinal logistic regression 
of three domain levels would be preferred, however, dichotomization is endorsed in the 
EQ-5D manual in this circumstance.23 
Logistic regression requires that the dependent variable be dichotomous and that 
each subgroup be mutually exclusive. It is recommended that at least 50 participants be 
included in the regression model for each additional independent variable. The 
independent variables were not assumed to be linearly related to the dependent variable 
and are not required to be of equal variance within each group.149 To complete logistic 
regression modelling the Stata command mfp: logistic was utilized with P=0.05. 
McFadden’s pseudo R2 was analyzed to assess model fit.150 Similar to linear regression 
modelling, variables were included in univariate and partially adjusted models to 
determine which were included in each domain specific fully adjusted logistic regression 
model. 
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Chapter 4: Results 
4.1 Population demographics and tobacco exposure 
Statistics describing the socio-demographic, medical history, and smoking 
exposure of all PanCan participants are found in Table 2, Table 3a and Table 3b. A total 
of 2537 participants enrolled into the PanCan. The study participants’ median age was 
62 (mean=62.3; range 50 to 76; IQR: 58 to 67) years. The sample was 55% males and 
45% females, and largely white (97.4%). At least some college education was completed 
by 47.1% of the sample. Over half of participants, 51.3%, were retired while 38.2% were 
employed. Median BMI of the sample was 25.8 kg/m2 (mean=26.6; range 14.0 to 53.8; 
IQR: 23.6 to 28.9) with 935 (36.9%) participants falling within the normal BMI range. 
Almost two thirds, 62.2%, of the sample defined themselves as current smokers. 
Current smokers were significantly younger than former smokers (mean=61.3 vs. 
mean=64.0, P<0.001) and smoked approximately 18 cigarettes daily, slightly less than 
one pack per day, within the 30 days prior to baseline. Collectively, the median smoking 
duration was 44 years (mean=44.1; SD= 5.9; IQR 40 to 48) with a median of 25 
cigarettes per day throughout their smoking lifetime (mean=24.7; SD= 10.6; IQR 20 to 
25). Approximately 1% of the study population smoked for fewer than 30 years. 
Compared to all other educational levels, participants with ≤8th grade education had the 
longest smoking duration, approximately 47 years, and the greatest number of cigarettes 
smoked per day (smoking period), approximately 21. The median time since quitting 
smoking for former smokers was 5 years (mean=5.8; SD=4.3; IQR 2 to 10). Unadjusted 
mean time since quitting smoking did not significantly differ among socio-demographic 
subgroups. However, individuals with a familial history of cancer quit smoking, on 
average, almost 1 year prior to those who did not (mean=6.3 vs. mean=5.6, P=0.01). 
In total, 2513 (99.1%) participants provided VAS baseline data (mean=76.8; 
SD=14.3; range: 1 to 100, IQR: 70 to 89) (Figure 6). Statistics describing VAS score 
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distribution by socio-demographic, medical history, exposure, symptom or morbidity 
variables are available in Table 4, Table 6, Table 8, and Table 10. 
Table 2. Distributions of continuous variables 
Variable N Median Mean SD Range IQR 
Socio-demographic 
and medical 
history 
      
Age 2537 62 62.3 5.8 50 to 76 58 to 67 
Body mass index 2537 25.8 26.6 4.4 14.0 to 53.8 23.6 to 28.9 
       
Exposures       
Cigarettes per day  
(last 30 days)* 
2531 18 17.8 10.8 0 to 80 10 to 25 
Cigarettes per day 
(smoking period) 
2537 25 24.7 10.7 1 to 100 20 to 25 
Smoking duration 2537 44 44.1 5.9 11 to 69 40 to 48 
Pack years
† 
2537 50 54.1 23.4 2.2 to 230 41 to 62.5 
Time since 
quitting
‡ 
2537 5 5.8 4.3 0.5 to 22 2 to 10 
Average alcoholic 
drinks per week 
2537 10 15.9 23.3 0 to 273 3 to 20 
Marijuana use 
(joints per month) 
2508 0 3.6 13.5 0 to 450 0 to 0 
       
Symptoms       
Total symptoms
† 
2537 3 2.8 2.1 0 to 9 1 to 4 
       
Morbidities       
FVC % predicted
† 
2517 0.9 0.92 0.17 0.35 to 1.76 0.81 to 1.03 
FEV1
 
% predicted 2517 0.8 0.82 0.19 0.15 to 1.68 0.70 to 0.94 
Total morbidities
† 
2537 3 2.8 2.0 0 to 14 1 to 4 
Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in one second; IQR, interquartile 
range; N, sample size; SD, standard deviation. 
* Current smokers only. 
† Excluded from regression modelling. 
‡ Former smokers only. 
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Figure 6. EQ VAS score boxplot with VAS score mean in red. 
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Table 3a. Smoking exposure by socio-demographic and medical history variables 
 
Socio-
demographic and 
medical history 
variables 
 Current 
(N=1579) 
 
Former 
(N= 958) 
 
 
 
 
Cigarettes per day 
(last 30 days)* 
 
Cigarettes per day 
(during smoking period) 
 
Smoking duration 
(years) 
 
Time since quitting      
(years)
† 
 
% N (%) N (%) P
‡ 
Mean (SD) P
‡ 
Mean (SD) P
‡ 
Mean (SD) P
‡ 
Mean (SD) P
‡ 
Age, mean (SD)   N=2537 61.3 (5.8) 64.0 (5.6) <0.001         
50 to 55 10.9 218 (79.0) 58 (21.0) <0.001 21.2 (11.1) <0.001 28.3 (11.5) <0.001 37.5 (3.2) <0.001 0.6 (2.0) <0.001 
56 to 60 19.8 369 (73.2) 135 (26.8) 20.1 (12.0)  27.2 (11.1)  41.3 (3.3)  0.9 (2.2)  
61 to 65 31.8 513 (63.5) 295 (36.5) 17.0 (10.4)  24.1 (10.4)  43.8 (4.7)  1.9 (3.5)  
66 to 70 25.5 345 (53.1) 305 (46.9) 15.5 (9.6)  23.2 (9.8)  46.5 (5.5)  3.3 (4.5)  
> 70 years 11.8 134 (44.8) 165 (55.2) 14.8 (8.6)  22.5 (10.1)  50.2 (6.0)  4.5 (5.0)  
             
Gender N=2537            
Female 44.8 705 (62.1) 431 (37.9) 0.028 16.9 (10.2) 0.010 23.1 (9.6) <0.001 43.5 (5.7) <0.001 5.9 (4.2) 0.306 
Male 55.2 874 (62.4) 527 (37.6)  18.5 (11.3)  26.1 (11.3)  44.5 (6.0)  5.7 (4.4)  
     
 
Race/ethnicity N=2526    
 
White 97.0 1519 (61.8) 941 (38.3) 0.005 17.8 (10.8) 0.105 24.8 (10.7) 0.130 44.1 (5.9) 0.956 5.9 (4.3) 0.055 
Non-white 3.0 52 (78.8) 14 (21.2)  16.1 (11.0)  22.2 (10.4)  44.3 (6.3)  4.0 (4.4)  
     
 
Education N=2537    
 
≤ 8
th
 grade 3.0 56 (74.7) 19 (25.3) 0.008 20.6 (14.8) <0.001 29.4 (13.3) <0.001 47.2 (7.0) 0.374 27.3 (12.7) <0.001 
9
th
 to 11
th
 grade 13.2 207 (61.8) 128 (38.2)  20.4 (11.9)  25.7 (12.2)  45.1 (6.1)  23.6 (9.4)  
High school  26.2 444 (66.9) 220 (33.1)  18.7 (10.8)  24.8 (10.0)  42.7 (5.9)  24.0 (9.0)  
Technical 
certificate 
10.6 168 (62.2) 102 (37.8) 
 
17.2 (10.2)  24.2 (10.7)  44.3 (6.2)  23.2 (9.7) 
 
Associate degree 19.2 291 (59.9) 195 (40.1)  18.0 (10.7)  24.7 (10.3)  44.1 (5.5)  23.3 (9.2)  
Bachelor’s 
degree 
17.0 
246 (57.1) 185 (42.9) 
 
15.8 (9.5)  24.3 (10.5)  44.0 (5.6)  
22.0 (8.7)  
Advanced degree 10.9 167 (60.5) 109 (39.5)  14.1 (9.1)  23.4 (10.1)  44.9 (5.0)  21.9 (8.5)  
Abbreviations: BMI, body mass index; N, sample size; P, P-value; SD, standard deviation. 
* Data presented for current smokers only. 
† Data presented for former smokers only. 
‡ P-values were computed for categorical comparisons using chi-square tests. P-values for comparisons of continuous variables age and BMI, which are non-
normally distributed, were calculated using non-parametric test for trend. 
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Abbreviations: BMI, body mass index; N, sample size; P, P-value; SD, standard deviation. 
* Data presented for current smokers only. 
† Data presented for former smokers only. 
‡ P-values were computed for categorical comparisons using chi-square tests. P-values for comparisons of continuous variables age and BMI, which are non-
normally distributed, were calculated using non-parametric test for trend. 
 
 
Table 3b. Smoking exposure by socio-demographic and medical history variables 
Socio-
demographic and 
medical history 
variables 
 
Current 
(N=1579) 
 
Former 
(N= 958) 
 
 
 
 
Cigarettes per day 
(last 30 days)
* 
 
Cigarettes per day 
(during smoking period) 
 
Smoking duration 
(years) 
 
Time since quitting      
(years)
† 
 
 % N (%) N (%) P
‡ 
Mean (SD) P
‡ 
Mean (SD) P
‡ 
Mean (SD) P
‡ 
Mean (SD) P
‡ 
Employment status  N=2520            
Employed 38.2 654 (67.9) 309 (32.1) <0.001 17.9 (10.4) 0.087 25.4 (10.9) 0.007 42.2 (5.2) <0.001 4.9 (4.4) 0.144 
Retired 51.3 702 (54.3) 592 (45.8)  16.5 (9.8)  23.7 (9.9)  45.8 (6.0)  6.4 (4.3)  
Unemployed 2.9 54 (75.0) 18 (25.0)  22.0 (10.8)  28.3 (11.9)  41.7 (4.9)  4.3 (3.9)  
Disabled 3.5 79 (88.8) 10 (11.2)  23.4 (14.6)  29.0 (13.0)  42.5 (4.5)  3.5 (3.1)  
Sick leave 0.5 11 (84.6) 2 (15.4)  30.5 (25.9)  28.9 (14.1)  42.3 (3.8)  1.5 (0.7)  
Other 3.5 67 (75.3) 22 (24.7)  18.3 (12.6)  23.9 (10.7)  43.9 (5.7)  5.5 (4.6)  
             
BMI, kg/m
2
, mean 
(SD) 
N=2537 27.4 (4.3) 26.0 (4.3) <0.001 
 
Underweight 1.1 22 (81.5) 5 (18.5) <0.001 18.7 (8.8) 0.005 23.4 (10.0) <0.001 45.8 (4.6) 0.162 5.0 (5.9) 0.970 
Normal 36.9 659 (70.5) 276 (29.5)  17.0 (10.3)  21.8 (10.8)  44.0 (5.9)  5.7 (4.4)  
Overweight 45.2 682 (59.5) 464 (40.5)  17.8 (10.5)  24.5 (10.2)  43.8 (5.9)  6.0 (4.3)  
Obese 16.9 216 (50.4) 213 (49.7)  20.2 (12.9)  28.4 (12.3)  44.9 (5.7)  5.4 (4.8)  
      
Familial cancer 
history 
N=2495     
No 66.4 1030 (62.2) 626 (37.8) 0.993 17.6 (10.5) 0.428 24.6 (10.6) 0.738 45.0 (5.5) <0.001 5.6 (4.3) 0.023 
Yes 33.6 522 (62.2) 317 (37.8)  18.1 (11.5)  25.1 (10.7)  42.1 (6.0)  6.3 (4.4)  
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4.2 Linear regression modelling 
4.2.1 Socio-demographic and medical history variables 
Statistics describing the relationship between socio-demographic and medical 
history variables, and VAS score are outlined in Table 4. Despite increasing age, the 
proportion of participants reporting VAS scores ≥80, the median, increased in successive 
age groups. Non-whites reported significantly lower VAS scores than white participants 
(mean=71.1 vs. mean=77.0; P=0.014). Of all socio-demographic subgroups, advanced 
degree holders had the greatest proportion of participants above the median (66.7%) 
and also reported the highest mean VAS score, 80.0. Employed (mean=78.0) and retired 
(mean=77.8) participants reported highest VAS scores among working groups. Disabled 
participants reported the lowest mean VAS score (59.5) of any socio-demographic 
subgroup and had the highest proportion (80.9%) of participants reporting VAS scores 
below the median. Participants in the normal BMI range reported the highest VAS 
scores. No significant differences in proportion or mean VAS score are observed 
between genders or participants with a familial history of cancer. 
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Table 4. Frequencies and descriptive statistics of VAS score by socio-demographic and 
medical history variables 
Socio-demographic 
and medical history 
variables  N (%) 
EQ-5D VAS score 
dichotomized at median
 
EQ-5D VAS score 
 
≤ 79 N (%) ≥ 80 N (%) P* Mean (SD; IQR) P* 
Age 2537 1085 1452    
50 to 54 276 (10.9) 140 (50.7) 136 (49.3) <0.001 73.9 (15.7; 70 to 75) <0.001 
55 to 59 504 (19.9) 242 (48.0) 262 (52.0)  75.0 (15.8; 70 to 80)  
60 to 64 808 (31.8) 339 (42.0) 469 (58.0)  77.2 (13.5; 70 to 80)  
65 to 69 650 (25.6) 252 (38.8) 398 (61.2)  78.5 (13.1; 70 to 80)  
> 70 299 (11.8) 112 (37.5) 187 (62.5)  77.7 (13.9; 70 to 80)  
      
Gender 2537 1085 1452    
Female 1136 (44.8) 472 (41.6) 664 (58.5) 0.264 77.2 (14.3; 70 to 80) 0.167 
Male 1401 (55.2) 613 (43.8) 788 (56.3)  76.4 (14.2; 70 to 80)  
      
Race/ethnicity 2526 1079 1447    
White 2460 (97.4) 1046 (42.5) 1414 (57.5) 0.225 77.0 (14.1; 70 to 80) 0.014 
Non-White 66 (2.6) 33 (50.0) 33 (50.0)  71.1 (17.8; 60 to 79)  
      
Education 2537 1085 1452    
8
th
 grade or less 75 (3.0) 43 (57.3) 32 (42.7) 0.001 72.0 (18.1;60 to 72) <0.001 
9
th
 to 11
th
 grade 335 (13.2) 164 (49.0) 171 (51.0)  74.1 (15.1; 66.5 to 80)  
High school graduate 664 (26.2) 288 (43.4) 376 (56.6)  76.5 (14.32; 70 to 80)  
Technical certificate 270 (10.6) 111 (41.1) 159 (58.9)  77.3 (14.4; 70 to 80)  
Associate degree/ 
Some college 
486 (19.2) 203 (41.8) 283 (58.2)  77.1 (15.0; 70 to 80)  
Bachelor’s degree 431 (17.0) 184 (42.7) 247 (57.3)  77.3 (12.7; 70 to 80)  
Advanced degree 276 (10.9) 92 (33.3) 184 (66.7)  80.0 (11.8; 74.5 to 80)  
      
Employment status 2520 1076 1444    
Working 963 (38.0) 400 (41.5) 563 (58.5) <0.001 78.0 (12.7; 70 to 80) <0.001 
Retired 1294 (51.0) 509 (39.3) 785 (60.7)  77.8 (13.7; 70 to 80)  
Unemployed 72 (2.8) 48 (66.7) 24 (33.3)  66.9 (17.9; 55 to 70)  
Disabled 89 (3.5) 72 (80.9) 17 (19.1)  59.5 (18.1; 50 to 60)  
Sick leave 13 (0.5) 9 (69.2) 4 (30.8)  60.8 (21.5; 40 to 60)  
Other 89 (3.5) 38 (42.7) 51 (57.3)  77.6 (14.2; 70 to 80)  
      
Body mass index 2537 1085 1452    
Underweight 27 (1.1) 18 (66.7) 9 (33.3) <0.001 70.6 (15.7; 60 to 70) <0.001 
Normal  935 (36.9) 323 (34.5) 612 (65.5)  79.0 (13.2; 70 to 80)  
Overweight  1146 (45.2) 491 (42.8) 655 (57.2)  77.0 (13.8; 70 to 80)  
Obese 429 (16.9) 253 (59.0) 176 (41.0)  71.7 (16.1; 65 to 75)  
      
Familial cancer history  2495 1063 1432    
No 1643 (66.5) 704 (42.5) 952 (57.5) 0.895 76.9 (14.2; 70 to 80) 0.781 
Yes 828 (33.5) 359 (42.8) 480 (57.2)  76.5 (14.5; 70 to 80)  
Abbreviations: IQR, interquartile range; N, sample size; P, P-value; SD, standard deviation. 
* P-values calculated for proportional comparisons with chi-squared test and non-parametric test of trend for 
comparisons of VAS score. 
Univariate and adjusted relationships between socio-demographic and medical 
history variables, and VAS score are described in Table 5. Significant differences were 
present in all nonparametric tests for trend and univariate regression models with the 
exception of gender and familial cancer history. Unadjusted models revealed a 
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significant non-linear relationship between age and VAS score (P=0.013). These effects 
were explained away after further adjustment, indicating a possible upstream association 
between age and VAS score. The locally weighted scatter plot smoothed relationship, 
which more accurately depicts the univariate relationship between age and VAS score, 
is depicted in Figure 7. 
 
Figure 7. Locally weighted scatterplot smoothing of VAS score and participant age at 
baseline 
Gender was statistically insignificant in all regression models. Race/ethnicity 
significantly predicted VAS score in all regression models. VAS scores tended to 
increase with education level, depicting a positive linear relationship. Compared to 
employed participants, the unemployed, disabled or persons on sick leave reported 
significantly lower VAS scores in all models. Unadjusted mean VAS scores for these 
groups ranged from approximately 11 to 18 points lower than employed or retired 
participants. VAS scores of retirees did not significantly different from the employed. 
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A significant non-linear relationship was observed between BMI and VAS score 
in univariate (P<0.001) and adjusted models (partially adjusted: P<0.001, fully adjusted: 
P=0.012, Figure 8). Familial cancer history was insignificant in all models tested. The 
fully adjusted model (to be described) which included all relevant variables (R2=0.284), 
explained 0.163 more variation in VAS score than the preliminary model which included 
only socio-demographic variables (R2=0.121). 
 
Figure 8. Fully adjusted non-linear relationship and confidence interval between BMI and 
EQ-5D VAS, N=2397
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Table 5. Univariate and linear regression models between socio-demographic and medical history factors, and VAS scores 
 
Socio-demographic and 
medical history variables 
Univariate model 
 
Partially adjusted model 
(N=2447, R
2
=0.121) 
 
Fully adjusted model 
(N=2397, R
2
=0.284)
* 
 
β (CI; P-value)
† 
β (CI; P-value)
†
 β (CI; P-value)
†
 
Age
 
   
1
st
 term 0.66 (0.33 to 0.98; <0.001)
‡ 
0.16 (0.09 to 0.24; 0.001) (P=0.084) 
2
nd
 term
 
-0.29 (-0.44 to -0.14; <0.001)
 ‡  
  
    
Gender (male vs. female) -0.79 (-1.91 to 0.33; 0.168) -0.91 (-1.86 to 0.037; 0.057) (P=0.054) 
    
Race/ethnicity (non-white vs. white) -2.06 (-3.26 to -0.85; 0.001) -5.44 (-8.31 to -2.56; 0.003) -3.88 (-7.59 to -0.18; 0.042) 
    
Education 0.88 (0.55 to 1.21; <0.001) 0.49 (0.19 to 0.80; 0.007) (P=0.939) 
    
Employment status (vs. employed)
 § 
   
Retired -0.15 (-1.30 to 1.00; 0.803) -1.06 (-2.64 to 0.53; 0.159) -0.67 (-1.85 to 0.51; 0.220) 
Unemployed -11.00 (-14.3 to -7.7; <0.001) -10.07 (-14.26 to -5.87; 0.001) -6.66 (-11.30 to 2.02; 0.012) 
Disabled -18.50 (-21.5 to -15.5; <0.001) -17.24 (-21.1 to -13.4; <0.001) -11.30 (-14.60 to -8.14; <0.001) 
Sick leave -17.20 (-24.7 to -9.69; <0.001) -16.01 (-29.9 to -2.09; 0.030) -12.15 (-20.68 to -3.62; 0.012) 
Other -0.37 (-3.36 to 2.62; 0.808) -0.59 (-4.04 to 2.85; 0.632) 0.04 (-4.38 to 4.45; 0.985) 
    
BMI
║ 
   
1
st
 term -117.00 (-155.0 to -80.6<0.001)
¶ 
-96.05 (-178.7 to -13.4; 0.029)
** 
-59.27 (-147.79 to 29.24; 0.157) 
†† 
2
nd
 term 373.00 (284.0 to 463.0; <0.001)
¶ 
324.8 (146.8 to 502.8; 0.004)
**
 212.85 (12.41 to 413.28; 0.040) 
†† 
    
Familial cancer history -0.35 (-1.54 to 0.85; 0.570) (P=0.365) Excluded 
Abbreviations: β, beta-coefficient; CI, confidence interval; N, sample size. 
* Final MFP linear regression model contains socio-demographic, smoking/alcohol exposure, morbidities and symptoms which were significantly associated with 
VAS score in partially adjusted MFP models. Only socio-demographic and medical history variables are displayed in this table. 
† Beta-coefficients, confidence intervals and p-values calculated using MFP linear regression models. 
‡ Age has a non-linear relationship with VAS score, and the following two terms in the regression model describes this relationship;  
𝑇𝑒𝑟𝑚 1 = [(
𝑎𝑔𝑒
10
)
3
− 242.101493] ∗ 0.6559657 
𝑇𝑒𝑟𝑚 2 = [(
𝑎𝑔𝑒
10
)
3
∗ ln (
𝑎𝑔𝑒
10
) − 442.9938443] ∗ (−0.2921975) 
§ When testing the total importance of employment status in the fully adjusted model, p< 0.001. 
║ When testing the total importance of BMI in the fully adjusted model, p< 0.001. 
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¶ BMI has a non-linear relationship with VAS score, and the following two terms in the regression model describes this relationship; 
𝑇𝑒𝑟𝑚 1 = [(
𝐵𝑀𝐼
10
)
−2
− 0.141899438] ∗ (-117.8698) 
𝑇𝑒𝑟𝑚 2 = [(
𝐵𝑀𝐼
10
)
−2
∗ ln (
𝐵𝑀𝐼
10
) − 0.138539022] * (373.8621) 
** BMI has a non-linear relationship with VAS score, and the following two terms in the regression model describes this relationship; 
𝑇𝑒𝑟𝑚 1 = [(
𝐵𝑀𝐼
10
)
−2
− 0.1371742112] * (-96.04738) 
𝑇𝑒𝑟𝑚 2 = [(
𝐵𝑀𝐼
10
)
−2
∗ ln (
𝐵𝑀𝐼
10
) − 0.1362485285] * (324.8107) 
†† BMI has a non-linear relationship with VAS score, and the following two terms in the regression model describes this relationship;  
𝑇𝑒𝑟𝑚 1 = [(
𝐵𝑀𝐼
10
)
−2
− 0.1371742112] * -59.27362 
𝑇𝑒𝑟𝑚 2 = [(
𝐵𝑀𝐼
10
)
−2
∗ ln (
𝐵𝑀𝐼
10
) − 0.1362485285] * 212.845
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4.2.2 Smoking and alcohol exposure 
Statistics describing the variation in EQ-5D VAS score by smoking and alcohol 
exposure variables are presented in Table 6. VAS score of current smokers was 
approximately 3 points lower than former smokers (mean=75.6 vs. mean=78.7; 
P<0.001). The proportion of participants reporting VAS scores below the median value 
decreased by approximately 10% between current and former smokers. Almost two 
thirds of the study sample reported smoking durations between 40 and 50 years, 
approximately 99% of participants reported smoking for at least 30 years. In the 30 days 
prior to baseline, slightly above 10% of current smokers smoked one pack of cigarettes 
(20 cigarettes) per day and approximately 50% smoked ≥ 1 pack of cigarettes per day. 
Of all PanCan participants, approximately 80% reported smoking at least one pack per 
day, on average, throughout the smoking period of their lifetime. Throughout the 
smoking period of their lifetime, former smokers reported smoking an average of almost 
4 more cigarettes per day than current smokers (mean=27.14 vs. mean=23.3; P<0.001). 
For all smoking exposure variables VAS scores tended to decrease as smoking 
exposure increased. 
Significant differences in VAS scores were apparent between PanCan 
participants based on alcohol consumption. Mean VAS score tended to decrease as 
alcohol consumption increased, however, participants consuming 0 to 2 drinks per week 
reported slightly lower VAS scores than participants consuming 3 to 10 alcoholic drinks 
per week. Regarding marijuana use, VAS score decreased with increased exposure to 
marijuana, mean VAS score was highest among non-users. 
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Table 6. Descriptive statistics of VAS score by exposure variables 
  
EQ-5D VAS score 
dichotomized at median 
 
EQ-5D VAS score 
 
Exposure variables N (%)  ≤ 79 N (%) ≥ 80 N (%) P* Mean (SD; IQR) P* 
Smoking Status 2537 1085 1452    
Former 958 (37.8) 351 (36.6) 607 (63.4) <0.001 78.7 (13.8; 70 to 80) <0.001 
Current 1579 (62.2) 734 (46.5) 845 (53.5)  75.6 (14.4; 70 to 80)  
       
Cigarettes per day 
(30 days before baseline) 2531 1083 1448 
   
Former smokers
†
 958 (37.8) 351 (36.6) 607 (63.4) <0.001 78.7 (13.8; 70 to 80) <0.001 
1
st
 quartile: 0 to 9 330 (13.0) 124 (37.6) 206 (62.4)  79.6 (12.3; 70 to 80)  
2
nd
 quartile: 10 to 19 463 (18.2) 199 (43.0) 264 (57.0)  76.4 (14.3; 70 to 80)  
3
rd
 quartile: 20 to 24 308 (12.1) 134 (43.5) 174 (56.5)  76.1 (14.3; 70 to 80)  
4
th
 quartile: >25 472 (18.6) 275 (58.3) 197 (41.7)  71.9 (15.2; 61 to 75)  
       
Cigarettes per day 
(during smoking period) 2537 1085 1452  
  
1
st
 quartile: 1 to 19 529 (23.9) 183 (34.6) 346 (65.4) <0.001 79.4 (12.7; 70 to 80) <0.001 
2
nd
 quartile: 20 to 24 641 (25.3) 264 (41.2) 377 (58.8)  77.7 (13.5; 70 to 80)  
3
rd
 quartile: 25 763 (30.1) 348 (45.6) 415 (54.4)  75.9 (14.4; 70 to 80)  
4
th
 quartile: > 25 604 (23.8) 290 (48.0) 314 (52.0)  74.5 (15.7; 70 to 80)  
       
Smoking duration, years 2537 1085 1452    
1
st
 quartile: ≤ 40 690 (27.2) 299 (43.3) 391 (56.7) 0.475 76.4 (15.0; 70 to 80) 0.971 
2
nd
 quartile: 41 to 44 699 (27.6) 307 (43.9) 392 (56.1)  76.6 (14.4; 70 to 80)  
3
rd
 quartile: 45 to 48 588 (23.2) 235 (40.0 353 (60.0)  77.8 (13.6; 70 to 80)  
4
th
 quartile: > 48 560 (22.1) 244 (43.6) 316 (56.4)  76.4 (13.9; 70 to 80)  
       
Time since quitting, years 2537 1085 1452    
Current smokers
‡
 1579 (62.2) 734 (46.5) 845 (53.5) <0.001 75.6 (14.4; 70 to 80) <0.001 
1
st
 quartile: 0 to 2 300 (11.8) 128 (42.7) 172 (57.3)  77.2 (14.6; 70 to 80)  
2
nd
 quartile: 3 to 5 203 (8.0) 76 (37.4) 127 (62.6)  78.3 (14.0; 70 to 80)  
3
rd
 quartile: 6 to 10 289 (11.4) 89 (30.8) 200 (69.2)  80.1 (12.6; 70 to 80)  
4
th
 quartile: 11 to 22 166 (6.5) 58 (34.9) 108 (65.1)  79.1 (13.8; 70 to 80)  
       Alcoholic drinks per week 2537 1085 1452    
1
st
 quartile: 0 to 2 708 (27.9) 282 (39.8) 426 (60.2) <0.001 77.6 (14.6; 70 to 80) <0.001 
2
nd
 quartile: 3 to 10 641 (25.3) 246 (38.4) 395 (61.6)  78.3 (13.7; 70 to 80)  
3
rd
 quartile: 11 to 20 558 (22.0) 242 (43.4) 316 (56.6)  76.4(13.4; 70 to 80)   
4
th
 quartile: > 20 630 (24.8) 315 (50.0) 315 (50.0)  74.6 (15.0; 70 to 75)  
       
Marijuana use  
(joints per month) 2508 1073 1435 
   
Non-users
§ 
1891 (75.4) 784 (41.5) 1107 (58.5) 0.034 77.5 (13.7; 70 to 80) 0.014 
1
st
 quartile: 1 to 4 210 (8.4) 86 (40.9) 124 (59.1)  76.9 (13.2; 60 to 80)  
2
nd
 quartile: 5 to 9 100 (4.0) 52 (52.0) 48 (48.0)  74.1 (14.9; 70 to 80)  
3
rd
 quartile: 10 to 20 159 (6.3) 80 (50.3) 79 (49.7)  73.2 (16.3; 65 to 75)  
4
th
 quartile: >20 148 (5.9) 71 (48.0) 77 (52.0)  73.1 (18.6; 68 to 77)  
Abbreviations: IQR, interquartile range; N, sample size; P, P-value; SD, standard deviation. 
* P-values calculated for proportional comparisons with chi-squared test and non-parametric test of trend for 
comparisons of VAS score. 
† Former smokers were excluded from quartile calculation. Mean EQ-5D VAS scores of former smokers 
were compared to current smokers of varying intensity. 
‡ Current smokers were excluded from quartile calculation. Mean EQ-5D VAS scores of current smokers 
were compared to time since quitting of varying intensity. 
§ Non-users were excluded in quartile calculation. Mean EQ-5D VAS scores of non-users were compared to 
current marijuana users of varying intensity. 
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Univariate and adjusted MFP linear regression data are presented in Table 7. 
Unadjusted regression models of all exposure variables, except for smoking duration, 
showed significant associations with VAS score. Average weekly alcohol consumption 
was the only exposure variable with a significant non-linear relationship with VAS score 
in unadjusted analysis. Exposure variables remaining significant after partial adjustment 
included cigarettes per day within the 30 days prior to baseline as well as cigarettes per 
day averaged throughout a participant’s smoking period and weekly alcohol 
consumption. Further adjustment for socio-demographic, morbidity and symptom 
variables explained away the effects of cigarettes per day averaged throughout a 
participant’s smoking period. Cigarettes consumed in the 30 days prior to baseline and 
weekly alcohol consumption were the only significant exposure variables of VAS score 
after full adjustment. The final model, which included all relevant variables (R2=0.284), 
explained 0.228 more variation in VAS score than the preliminary smoking and alcohol 
exposure model (R2=0.056). 
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Table 7. Univariate and multivariable fractional polynomial linear regression models between smoking and alcohol exposure 
variables and EQ-5D VAS scores 
Smoking/Alcohol 
Exposure 
Univariate Model 
  
Partially Adjusted Model* 
(N=2481, R
2
=0.056) 
  
Final Adjusted Model† 
(N=2397, R
2
=0.284) 
 
β (CI; P-value)
‡ 
 β (CI; P-value)
‡ 
 β (CI; P-value)
‡
 
Cigarettes per day 
(last 30 days) 
-0.22 (-0.26 to -0.17; <0.001)  -0.16 (-0.21 to -0.11; <0.001)  -0.09 (-0.15 to -.004; 0.005) 
      
Cigarettes per day 
(during smoking period) 
-0.18 (-0.23 to -0.13; <0.001)  -0.15 (-0.19 to -0.10; <0.001)  (P=0.580) 
      
Smoking duration 
(years) 
0.0003 (-0.095 to 0.095; 0.995)  (P=0.41)  Excluded 
      
Time since quitting 
(years) 
0.39 (0.24 to 0.53; <0.001)  0.14 (0.08 to 0.42; 0.157)  (P=0.674) 
      
Alcoholic drinks per week 
 
    
1
st
 term -4.11e
-6
 (-5.89e
-6
 to -2.33e
-6
; <0.001)
§ 
 -0.05 (-0.07 to -0.02; 0.002)  -0.03 (-0.05 to -0.01; 0.01) 
2
nd
 term -10.5
4 
(-13.58 to -7.43; <0.001)
§
     
      
Marijuana use  
(joints per month)  
-1.31 (-1.81 to -0.79; <0.001)
║
  -0.04 (-0.09 to 0.02; 0.190)  (P=0.465) 
Abbreviations: β, beta-coefficient; CI, confidence interval; N, sample size; 
* Independent variables included in MFP linear regression modelling contain only smoking and alcohol exposures. 
† MFP linear regression model contains socio-demographic, smoking/alcohol exposure, morbidities and symptoms which were significantly associated with VAS 
score in partially adjusted MFP models. Only smoking and alcohol exposure variables are displayed in this table. 
‡ Beta-coefficients, confidence intervals and p-values calculated using multivariable fractional polynomial regression models. 
§ Average weekly alcohol consumption has a non-linear relationship with VAS score, and the following two terms in the regression model describe this 
relationship; 
𝑇𝑒𝑟𝑚 1 = [(
𝑑𝑟𝑖𝑛𝑘𝑠 𝑝𝑒𝑟 𝑤𝑒𝑒𝑘 + 0.099
100
)
−2
− 39.1] ∗ (−4.11𝑒−6) 
𝑇𝑒𝑟𝑚 2 = [(
𝑑𝑟𝑖𝑛𝑘𝑠 𝑝𝑒𝑟 𝑤𝑒𝑒𝑘 + 0.099
100
)
^.5
− 0.399] ∗ (−10.50326) 
 
║ Average monthly marijuana use has a non-linear relationship with VAS score, and the following term in the regression model describes this relationship; 
𝑇𝑒𝑟𝑚 1 = [
ln(𝑚𝑎𝑟𝑖𝑗𝑢𝑎𝑛𝑎 𝑢𝑠𝑒 + 1)
100
] + 3.079201368
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4.2.3 Morbidities and quality of life (VAS scores) 
Descriptive statistics outlining the relationship between pulmonary, 
cardiovascular and other morbidities, and VAS scores are available in Tables 8a and 8b. 
The most prevalent morbidities among the PanCan population were 
hypercholesterolemia (42%), arthritis (40%), hypertension (36%), allergies (31%) and 
COPD (21%). Mean number of morbidities tended to be higher among older participants 
and those with higher educational attainment. Significantly fewer morbidities were 
reported by males (mean=2.53 vs. mean=3.21; P<0.001) and employed participants 
(P<0.001) than their counterparts. 
Mean number of morbidities increased among participants smoking more 
cigarettes per day in the 30 days prior to baseline (P<0.001) and those with greater 
number of cigarettes smoked per day throughout the entire smoking period of their 
lifetime (P=0.003). However, former smokers reported significantly more morbidities than 
current smokers (mean=3.03 vs. mean=2.71; P<0.001). A larger proportion of 
participants without morbidities reported VAS scores greater than the median value, 80, 
compared to those with morbidities. As the number of total morbidities increased, VAS 
scores progressively decreased. Participants with increased pulmonary function, FEV1 
percent predicted or FVC percent predicted, more commonly reported VAS scores 
greater than the median value in addition to reporting higher mean VAS scores. 
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Table 8a. Frequencies and descriptive statistics of VAS score by morbidities and 
pulmonary function variables 
  EQ-5D VAS score  
dichotomized at median 
 
EQ-5D VAS score
 
 Morbidity variables N (%) ≤ 79 N (%) ≥ 80 N (%) P* Mean (SD; IQR) P* 
 Cardiovascular morbidities       
Stroke 2505 1080 1449    
No 2459 (97.2) 1043 (42.4) 1416 (57.6) 0.082 76.9 (14.2; 70 to 80) 0.031 
Yes 70 (2.8) 37 (52.9) 33 (47.1)  73.3 (14.4; 63 to 75)  
       
Angina 2502 1078 1448    
No 2358 (93.3) 977 (41.4) 1381 (58.6) <0.001 77.2 (14.1; 70 to 80) <0.001 
Yes 168 (6.7) 101 (60.1) 67 (39.9)  71.6 (15.5; 60 to 75)  
       
Myocardial infarction 2530 1080 1450    
No 2370 (92.8) 992 (41.9) 1378 (58.1) 0.001 77.1 (14.0; 70 to 80) 0.001 
Yes 160 (7.2) 88 (55.0) 72 (45.0)  72.2 (17.1; 65 to 75)  
       
Hypercholesterolemia 2507 1080 1451    
No 1465 (58.0) 583 (39.8) 882 (60.2) 0.001 77.9 (13.8; 70 to 80) <0.001 
Yes 1066 (42.0) 497 (46.6) 569 (53.4)  75.3 (14.7; 70 to 80)  
       
Hypertension 2525 1075 1450    
No 1614 (64.0) 629 (39.0) 985 (61.0) <0.001 78.0 (13.8; 70 to 80) <0.001 
Yes 911 (36.0) 446 (49.0) 465 (51.0)  74.9 (14.7; 70 to 80)  
       
Congestive heart failure 2528 1080 1448    
No 2511 (99.3) 1074 (42.8) 1437 (57.2) 0.534 76.8 (14.2; 70 to 80) 0.229 
Yes 17 (0.7) 6 (35.3) 11 (64.7)  79.6 (16.6; 70 to 85)  
       
Peripheral vascular 
disease 2503 1078 1449 
   
No 2422 (95.8) 1017 (42.0) 1405 (58.0) 0.001 77.1 (14.1; 70 to 80) 0.001 
Yes 105 (4.2) 61 (58.1) 44 (41.9)  71.2 (17.2; 62.5 to 75)  
       
 Pulmonary morbidities       
Asthma 2503 1079 1448    
No 2282 (90.4) 945 (41.4) 1337 (58.6) <0.001 77.4 (13.8; 70 to 80) <0.001 
Yes 245 (9.6) 134 (54.7) 111 (45.3)  71.3 (17.1; 60 to 75)  
       
COPD 2501 1077 1448    
No 1993 (79.0) 896 (38.8) 1330 (61.2) <0.001 78.1 (13.5; 70 to 80) <0.001 
Yes 532 (21.0) 181 (57.1) 118 (42.9)  72.2 (15.8; 65 to 75)  
       
Pulmonary fibrosis 2532 1082 1450    
No 2529 (99.9) 1080 (42.7) 1449 (57.3) 0.402 76.8 (14.2; 70 to 80) 0.161 
Yes 3 (0.1) 2 (66.7) 1 (33.3)  56.7 (32.1; 20 to 70)  
       
 Pulmonary function       
FEV1 % predicted 2517 1077 1440    
1
st
 quartile: 0.939 to 1.684 630 (25.0) 198 (31.5) 431 (68.5) <0.001 80.1 (12.8; 60 to 75) <0.001 
2
nd
 quartile: 0.825 to 0.938 629 (25.0) 233 (37.0) 396 (63.0)  78.7 (13.3; 70 to 80)  
3
rd
 quartile: 0.703 to 0.824 629 (25.0) 279 (44.4) 350 (55.6)  76.6 (13.5; 70 to 80)  
4
th
 quartile: 0.151 to 0.702 629 (25.0) 367 (58.2) 263 (41.8)  71.7 (16.1; 70 to 80)  
       
FVC percent predicted 2517 1077 1440    
1
st
 quartile: 1.03 to 1.76 629 (25.0) 226 (35.9) 403 (64.1) <0.001 78.6 (13.5; 65 to 75) <0.001 
2
nd
 quartile: 0.919 to 1.028 629 (25.0) 230 (36.5) 400 (63.5)  78.5 (13.9; 70 to 80)  
3
rd
 quartile: 0.811 to 0.919  630 (25.0) 281 (44.7) 348 (55.3)  77.3 (13.1; 70 to 80)  
4
th
 quartile: 0.346 to 0.811  629 (25.0) 340 (54.0) 289 (46.0)  72.8 (15.8; 70 to 80)  
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; 
FVC, forced vital capacity; IQR, interquartile range; N, sample size; P, P-value; SD, standard deviation. 
* P-values calculated using chi-square tests for categorical comparisons and non-parametric test of trend for 
comparisons involving continuous data. 
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Table 8b. Frequencies and descriptive statistics of VAS score by morbidities 
 
Morbidity 
variables  
EQ-5D VAS score dichotomized at 
median 
 
EQ-5D VAS score 
 
 N (%) ≤ 79 N (%) ≥ 80 N (%) P* Mean (SD; IQR) P* 
Other morbidities       
Liver disease 2529 1081 1448    
No 2383 (94.3) 1008 (42.3) 1375 (57.7) 0.068 77.0 (14.1; 70 to 80) 0.036 
Yes 146 (5.7) 73 (50.0) 73 (50.0)  74.0 (15.9; 70 to 75)  
       
Kidney disease 2522 1078 1444    
No 2479 (98.3) 1060 (42.8) 1419 (57.2) 0.906 76.8 (14.2; 70 to 80) 0.631 
Yes 43 (1.7) 18 (41.9) 25 (58.1)  75.1 (15.5; 70 to 80)  
       
Osteoporosis 2530 1082 1448    
No 2135 (84.3) 910 (42.6) 1225 (57.4) 0.734 76.9 (14.2; 70 to 80) 0.313 
Yes 395 (15.7) 172 (43.5) 223 (56.5)  76.1 (14.5; 70 to 80)  
       
Arthritis 2529 1082 1447    
No 1506 (59.6) 510 (38.0) 934 (62.0) <0.001 78.3 (13.5; 70 to 80) <0.001 
Yes 1023 (40.4) 572 (49.8) 513 (50.2)  74.6 (15.1; 70 to 77)  
       
Allergy 2530 1081 1449    
No 1745 (69.0) 716 (41.0) 1029 (59.0) 0.010 77.3 (14.1; 70 to 80) 0.010 
Yes 785 (31.0) 365 (53.5) 420 (46.5)  75.7 (14.5; 70 to 80)  
       
Diabetes 2529 1078 1451    
No 2301 (91.0) 949 (41.2) 1352 (58.8) <0.001 77.2 (14.1; 70 to 80) <0.001 
Yes 228 (9.0) 129 (56.6) 99 (43.4)  72.6 (14.8; 65 to 75)  
       
Anemia 2531 1080 1451    
No 2319 (91.6) 977 (42.1) 1342 (57.9) 0.069 77.0 (14.2; 70 to 80) 0.008 
Yes 212 (8.4) 103 (48.6) 109 (51.4)  74.4 (14.8; 66 to 80)  
       
Morbidities total 2533 1082 1451    
0 274 (11.0) 84 (31.3) 190 (68.7) <0.001 81.1 (13.4; 75 to 80) <0.001 
1 413 (16.3) 135 (32.7) 278 (67.3)  79.7 (12.2;75 to 80)  
2 559 (22.0) 206 (36.9) 353 (63.2)  78.8 (12.6; 70 to 80)  
3 467 (18.4) 207 (44.3) 260 (55.7)  76.4 (13.5; 70 to 80)  
4 327 (12.9) 153 (46.8) 174 (53.2)  75.8 (14.4; 70 to 80)  
5 240 (9.5) 130 (54.2) 110 (45.8)  72.8 (15.5; 65 to 75)  
6 120 (4.7) 75 (62.5) 45 (37.5)  70.6 (17.4; 60 to 71)  
≥7 133 (5.2) 92 (69.2) 41 (30.8)  66.9 (16.7; 59 to 70)  
Abbreviations: IQR, interquartile range; N, sample size; P, P-value; SD, standard deviation. 
* P-values calculated using chi-square tests for categorical comparisons and non-parametric test of trend for 
comparisons involving continuous data. 
 
Statistics describing the univariate and adjusted relationships between 
cardiovascular, pulmonary, and other morbidities, and VAS scores from linear regression 
modelling are available in Table 9. All morbidities were significantly inversely associated 
with VAS score in univariate analysis except for osteoporosis and kidney disease. Many 
variables were no longer significant after adjusting for other morbidities. In the final 
model which adjusts for all socio-demographic, exposure, morbidity and symptom 
factors, high cholesterol (P=0.015), myocardial infarction (P=0.015), peripheral vascular 
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disease (P=0.018), arthritis (P=0.036) and low FEV1 percent predicted (P=0.006) were 
significantly associated with lower VAS scores. In univariate and preliminary morbidity-
adjusted regression models, FEV1 percent predicted, had a significant linear relationship 
with VAS score. However, in the fully adjusted model, a significant non-linear 
relationship became apparent (P=0.027) (Figure 9). The partially adjusted morbidity 
regression model explains 0.106 of the variation in VAS score, 0.174 less than the fully 
adjusted regression model. 
 
 
Figure 9. Adjusted non-linear relationship between forced expiratory volume in one 
second percent predicted and EQ-5D VAS score
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Table 9. Univariate and linear regression models between morbidities variables and EQ-5D VAS scores 
 
Univariate Model 
 
Preliminary Model*
 
(N=2432, R
2
=0.106) 
 
Final Adjusted Model
† 
(N=2397, Adj. R
2
=0.284) 
 
Morbidities β (CI; P-value)
‡ 
β (CI; P-value)
‡ 
β (CI; P-value)
‡ 
Cardiovascular     
Stroke -3.63 (-7.02 to -0.25; 0.035) (P=0.815) Excluded 
CHD -5.12 (-7.24 to -2.99; <0.001) (P=0.457) Excluded 
Angina -5.61 (-7.84 to -3.38; <0.001) -2.49 (-5.76 to 0.77; 0.114) (P=0.500) 
Myocardial infarction -4.90 (-7.2 to -2.61; <0.001) -3.37 (-6.14 to -0.60; 0.024) -2.64 (-4.60 to -0.68; 0.015) 
Hypercholesterolemia -2.58 (-3.71 to -1.46; <0.001) -1.32 (-2.22 to -0.42; 0.010) -1.15 (-1.99 to -0.30; 0.015) 
Hypertension -3.11 (-4.26 to -1.95; <0.001) (P=0.237) Excluded 
CHF 2.86 (-3.94 to 9.66; 0.410) 5.24 (-2.76 to 13.25; 0.165) (P=0.216) 
PVD -5.87 (-8.66 to -3.08; <0.001) -3.85 (-6.07 to -1.63; 0.005) -2.61 (-4.63 to -0.59; 0.018) 
       
Pulmonary       
Asthma -6.15 (-8.03 to -4.27; <0.001) -2.97 (-6.57 to 0.62; 0.091) (P=0.182) 
COPD -5.91 (-7.26 to -4.56; <0.001) -3.16 (-5.30 to -1.02; 0.010) (P=0.635) 
Pulmonary fibrosis -20.16 (-36.29 to -4.02; 0.014) (P=0.243) Excluded 
Pneumonia -3.62 (-4.87 to -2.36; <0.001) -1.68 (-3.09 to -0.26; 0.026) Excluded 
FEV1 % predicted
§
 16.79 (13.83 to 19.75; <0.001) 12.2 (6.89 to 17.41; 0.001) -3.70 (-5.95 to -1.45; 0.006) 
       
Other        
Liver disease -3.01 (-5.4 to -0.61; 0.014) (P=0.135) (P=0.933) 
Kidney disease -1.75 (-6.10 to 2.6; 0.430) (P=0.780) Excluded 
Osteoporosis -0.86 (-0.24 to 0.68; 0.274) (P=0.491) Excluded 
Arthritis -3.72 (-4.85 to -2.59; <0.001) -3.01 (-4.55 to -1.47; 0.002) -1.78 (-3.40 to -0.15; 0.036) 
Allergy -1.53 (-2.73 to -0.32; 0.013) (P=0.593) Excluded 
Diabetes -4.68 (-6.62 to -2.73; <0.001) (P=0.052) (P=0.279) 
Anemia -2.62 (-4.62 to -0.61; 0.011) (P=0.283) Excluded 
Blood disease -4.36 (-8.40, -0.34; 0.033) (P=0.131) (P=0.192) 
Abbreviations: CHD, coronary heart disease; CHF; congestive heart failure; COPD; chronic obstructive pulmonary disease; FEV1
 
% predicted, forced 
expiratory volume in one second percent predicted; N, sample size; PVD, peripheral vascular disease. 
* Variables eligible for inclusion in preliminary linear regression models are limited to the pulmonary, cardiovascular and ‘other’ morbidities variables listed 
in Table 1 as well as FEV1 percent predicted. 
† Linear regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly associated with VAS 
score in partially adjusted MFP models. 
‡ Beta-coefficients, confidence intervals and p-values calculated using MFP linear regression models. 
§ FEV1, percent predicted, has a non-linear relationship with VAS score and is described by the following term; 𝑇𝑒𝑟𝑚 1 = (𝐹𝐸𝑉−1 − 1.25) ∗ (−3.698979) 
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4.2.4 Symptoms 
Statistics describing VAS score by symptom are presented in Table 10 and 
regression associations are described in Table 11. The most prevalent symptoms were 
coughing (52.4%), phlegm (46.2%), dyspnea (45.3%), fatigue (39.2%) and wheezing 
(37.6%). Older participants reported significantly fewer symptoms (P<0.001); those aged 
50 to 55 (mean=3.69) reported approximately one more symptom than those ≥70 years 
(mean=2.52). Participants with lower education or those who are not retired also tended 
to report greater symptoms. Former smokers experienced significantly fewer symptoms 
than current smokers (mean=2.15 vs. mean=3.21; P<0.001). Number of symptoms 
reported also significantly increased (P<0.001) as participants reported greater number 
of cigarettes smoked in the 30 days prior to baseline, and greater number of cigarettes 
smoked per day, throughout the smoking period of participant’s lifetime. 
Participants experiencing any symptom were more likely to report VAS scores 
below the median VAS value, 80, compared to those who were symptom free. 
Furthermore, mean VAS score of symptom-affected participants was significantly lower 
for all symptoms except hemoptysis which was also associated with lower VAS score but 
because of small numbers only approached significance. Mean VAS score significantly 
decreased as the number of reported symptoms increased.  
All symptoms were significantly, inversely associated with VAS score in 
univariate analysis. After adjusting for all symptoms, dyspnea (P<0.001), phlegm 
(P=0.001), chest pain (P<0.007), having a poor appetite (P=0.017) and feeling fatigued 
(P<0.0001) remained significant. In comparison to all other partially adjusted regression 
models, symptoms explained the most variation in VAS score. The final model, which 
included all relevant variables (R2=0.284), explained 0.094 more variation in VAS score 
than the preliminary symptoms model (R2=0.190). 
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Table 10. Descriptive statistics of VAS score by symptoms variables 
  EQ-5D VAS score 
dichotomized at median 
 
EQ-5D VAS scores 
 
Symptom N (%) ≤ 79 N (%) ≥ 80 N (%) P* Mean (SD; IQR) P* 
Dyspnea 2531 1082 1449    
No 1384 (54.7) 409 (29.5) 975 (70.5) <0.001 80.1 (11.8; 75 to 80) <0.001 
Yes 1147 (45.3) 673 (58.7) 474 (41.3)  71.8 (15.3; 65 to 75)  
       
Cough 2531 1082 1449    
No 1204 (47.6) 428 (35.6) 776 (64.5) <0.001 79.2 (12.9; 70 to 80) <0.001 
Yes 1327 (52.4) 654 (49.3) 673 (50.7)  74.6 (15.0; 70 to 80)  
       
Phlegm 2530 1082 1448    
No 1360 (53.8) 479 (35.2) 881 (64.8) <0.001 79.2 (13.0; 70 to 80) <0.001 
Yes 1170 (46.2) 603 (51.5) 567 (48.5)  74.0 (15.1; 68 to 75)  
       
Hemoptysis 2529 1082 1447    
No 2485 (98.2) 1056 (32.5) 1429 (57.5) 0.027 76.9 (14.1; 70 to 80) 0.135 
Yes 44 (1.8) 26 (59.1) 18 (40.9)  72.0 (20.2; 60.5 to 75)  
       
Hoarseness 2530 1082 1448    
No 1878 (74.3) 728 (38.8) 1150 (61.2) <0.001 78.1 (13.5; 70 to 80) <0.001 
Yes 652 (25.7) 354 (54.3) 298 (45.7)  73.1 (15.6; 65 to 75)  
       
Wheeze 2530 1082 1448    
No 1577 (62.4) 543 (34.4) 1034 (65.6) <0.001 79.5 (12.9; 70 to 80) <0.001 
Yes 953 (37.6) 539 (56.6) 414 (43.4)  72.3 (15.2; 65 to 75)  
       
Chest pain 2524 1078 1446    
No 2088 (82.8) 823 (39.4) 1265 (60.6) <0.001 78.0 (13.5; 70 to 80) <0.001 
Yes 436 (17.2) 255 (58.5) 181 (41.5)  70.8 (16.2; 60 to 75)  
       
Poor appetite 2529 1081 1448    
No 2338 (92.5) 950 (40.6) 1388 (59.4) <0.001 77.6 (13.9; 70 to 80) <0.001 
Yes 191 (7.5) 131 (68.6) 60 (31.4)  67.5 (15.7; 60 to 70)  
       
Fatigue 2530 1082 1448    
No 1536 (60.8) 492 (32.0) 1044 (68.0) <0.001 80.7 (11.6; 75 to 80) <0.001 
Yes 994 (39.2) 590 (59.4) 404 (40.6)  70.7 (15.8; 60 to 70)  
       
Weight loss 2527 1080 1447    
No 2311 (91.4) 966 (41.8) 1345 (58.2) 0.002 77.1 (14.1; 70 to 80 0.001 
Yes 216 (8.6) 114 (52.8) 102 (47.2)  73.6 (15.0; 66 to 75)  
       
Symptoms total 2532 1450 1082    
0 440 (17.6) 87 (19.8) 353 (80.2) <0.001 83.9 (10.0; 80 to 85) <0.001 
1 377 (14.8) 122 (32.4) 255 (67.6)  80.6 (12.2; 70.5 to 80)  
2 408 (16.1) 135 (33.1) 273 (66.9)  79.7 (12.4;75 to 80)  
3 383 (15.1) 170 (44.4) 213 (55.6)  76.6 (13.1; 70 to 80)  
4 335 (13.2) 164 (49.0) 171 (51.0)  74.9 (12.7; 70 to 80)  
5 274 (10.8) 180 (65.7) 94 (34.3)  70.6 (15.0; 60 to 70)  
≥ 6 315 (12.4) 224 (71.1) 91 (28.9)  66.2 (17.1; 60 to 70)  
Abbreviations: IQR, interquartile range; N, sample size; P, P-value; SD, standard deviation. 
* P-values calculated using chi-square test for categorical comparisons and non-parametric test of trend for 
continuous variable comparisons. 
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Table 11. Univariate and multivariate linear regression models between symptoms variables and EQ-5D VAS scores 
Symptoms 
 
Univariate Model 
 
Partially Adjusted Model*
 
(N= 2497, R
2
=0.190) 
 
Final Adjusted Model
† 
(N= 2397, R
2
=0.284) 
 
β (CI; P-value)
‡
 β (CI; P-value)
‡ 
β (CI; P-value)
‡ 
Dyspnea -9.22 (-10.3 to -8.16; <0.001) -4.77 (-6.42 to -3.12; <0.001) -3.30 (-5.68 to -0.92; 0.013) 
    
Cough -4.59 (-5.7 to -3.49; <0.001) (P=0.719) Excluded 
    
Phlegm -5.23 (-6.33 to -4.13; <0.001) -1.56 (-2.28 to -0.84; 0.001) -1.35 (-2.18 to -0.52; 0.006) 
    
Hemoptysis -4.87 (-9.12 to -0.63; 0.025) (P=0.811) Excluded 
    
Hoarseness -5.02 (-6.28 to -3.75; <0.001) -1.15 (-2.83 to 0.53; 0.150) (P=0.053) 
    
Wheeze -7.13 (-8.25 to -6.02; <0.001) -2.26 (-3.87 to -0.65; 0.014) (P=0.096) 
    
Chest pain -7.21 (-8.67 to -5.76; <0.001) -2.38 (-3.79 to -0.97; 0.005) -2.59 (-3.70 to -1.49; 0.001) 
    
Poor appetite -10.06 (-12.1 to -7.99; <0.001) -4.32 (-7.63 to -1.02; 0.018) -4.14 (-7.31 to -0.96; 0.018) 
    
Fatigued -10.03 (-11.1 to -8.96; <0.001) -6.43 (-7.69 to -5.17; <0.001) -5.84 (-7.04 to -4.64; <0.001) 
    
Weight loss -3.53 (-5.51 to -1.54; 0.001) (P=0.632) Excluded 
Abbreviations: β, beta-coefficient; CI, confidence interval; N, Sample Size. 
* Linear regression model contains only symptoms variables. 
† Linear regression model contains socio-demographic, smoking and alcohol exposure, morbidities and symptoms which were significantly associated with VAS 
score in partially adjusted MFP models. Only symptoms variables are displayed in this table. 
‡ Beta-coefficients, confidence intervals and p-values calculated using linear regression models. 
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4.2.5 Summary of final linear regression model 
All variables significant in the fully adjusted model are presented in Figure 10 and 
Table 12. In total, 15 socio-demographic, medical history, exposure, morbidity and 
symptom variables were associated with VAS score in the fully adjusted model. 
Upstream and downstream associations between all variables and VAS score are 
previously described. Several variables exhibited strong associations with VAS score, 
particularly employment status (unemployed, disabled or on sick leave) and symptoms 
variables dyspnea, poor appetite or fatigue. Non-linear relationships were observed 
between BMI and VAS score as well as FEV1 percent predicted and VAS score. The 
final regression model explained 0.284 of the variation in VAS scores. 
 
 
Figure 10. Adjusted effect estimates of variables significantly linearly associated with 
VAS score 
* To ease interpretation, estimate reflects the association between drinking 16 alcoholic drinks per week, the 
PanCan mean, and VAS score. † To ease interpretation, estimate reflects the association between smoking 
20 cigarettes (one pack) per day in the 30 days prior to baseline. 
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Table 12. Variables significantly associated with VAS score in the fully adjusted MFP 
linear regression model, N=2397, R2=0.284 
Significant independent variables Beta-coefficient (confidence interval; P-value)* 
Socio-demographics and 
medical history 
   
Race/ethnicity  
non-white vs. white -3.88 (-7.59 to -0.18; 0.042) 
    
Employment status    
Employed Referent 
Retired -0.67 (-1.85 to 0.51; 0.220) 
Unemployed -6.66 (-11.30 to -2.02; 0.012) 
Disabled -11.37 (-14.59 to -8.14; <0.001) 
Sick leave -12.15 (-20.68 to -3.62; 0.012) 
Other -0.03 (-4.37 to 4.45; 0.985) 
    
Body mass index    
1
st
 term
† 
-59.27 (-147.79 to 29.24; 0.157) 
2
nd
 term
† 
212.85 (12.41 to 413.28; 0.040) 
    
Smoking and alcohol exposures    
Cigarettes per day (last 30 days) -0.09 (-0.15 to -0.04; 0.005) 
Alcoholic drinks per week -0.04 (-0.05 to -0.01; 0.004) 
    
Morbidities    
Myocardial infarction -2.64 (-4.60 to -0.68; 0.015) 
Hypercholesterolemia -1.15 (-1.99 to -0.30; 0.015) 
Peripheral vascular disease -2.61 (-4.63 to -0.59; 0.018) 
Arthritis -1.78 (-3.40 to -0.15; 0.036) 
FEV1 percent predicted
‡ 
-0.04 (-0.06 to -0.01; 0.006) 
  
Symptoms    
Dyspnea -3.30 (-5.68 to -0.92; 0.013) 
Phlegm -1.35 (-2.18 to -0.52; 0.006) 
Chest pain -2.59 (-3.70 to -1.49; 0.001) 
Poor appetite -4.14 (-7.31 to -0.96; 0.018) 
Fatigued -5.84 (-7.04 to -4.64; <0.001) 
Abbreviations: FEV1, forced expiratory volume in one second; N, sample size;. 
* Beta-coefficients, confidence intervals and P-values were calculated using linear regression with 
a MFP selection procedure. 
† BMI has a non-linear relationship with VAS score, and the following two terms in the regression 
model describe this relationship; 
𝑇𝑒𝑟𝑚 1 = [(
𝐵𝑀𝐼
10
)
−2
− 0.1371742112] * -59.27362) 
𝑇𝑒𝑟𝑚 2 = [(
𝐵𝑀𝐼
10
)
−2
∗ ln (
𝐵𝑀𝐼
10
) − 0.1362485285] * (212.845) 
‡ FEV1, percent predicted has a non-linear relationship with VAS score, and the following term in 
the regression model describes this relationship; 
𝑇𝑒𝑟𝑚 1 = [(𝐹𝐸𝑉1 𝑝𝑒𝑟𝑐𝑒𝑛𝑡 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑)
−1 − 1.25] ∗ (-3.698979) 
 
4.4 Interaction 
A priori interactions between gender and smoking exposures (smoking duration, 
daily number of cigarettes consumed over the smoking lifetime and within the previous 
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30 days) as well as smoking exposure and morbidity subgroups were insignificant. 
Interactions between having diabetes and smoking exposures were also insignificant. 
4.5 Bootstrapping 
To assess stability of the final regression model, 1000 bootstrap replications were 
prepared. Although all variables were included in bootstrap analysis, bootstrap inclusion 
fractions (BIF) only for those variables significantly associated with VAS score in the final 
linear regression model or included in greater than 50% of bootstrap replications are 
presented in Table 13. BIF, mean effect estimates and mean exponents for all variables 
assessed in regression analysis are available in Appendix 1a and Appendix 1b. Of all 
variables assessed, 14 have BIF greater than 50%. Pulmonary fibrosis was not 
significant in the full regression model but did yield a high BIF, 58.2%. Alternatively, 
hypercholesterolemia (BIF=46.8%) and peripheral vascular disease (BIF=46.3%), which 
were significantly associated with VAS score in the full regression model, were included 
in less than 50% of bootstrap replications. Several significant variables in the full 
regression model produced BIF greater than 90%: BMI (99.9%), dyspnea (100%), chest 
pain (91.6%), poor appetite (96.6%), fatigue (100%), arthritis (92%) and FEV1 percent 
predicted (99.5%). 
A non-linear association between BMI and VAS score was present in 62.3% of all 
bootstrap replications (Appendix 2). Linear relationships most commonly described the 
relationships between cigarettes smoked per day in the last 30 days, weekly number of 
alcoholic drinks, and VAS score (Appendix 3 and Appendix 4). FEV1 percent predicted 
was a significant predictor of VAS score in 99.5% of bootstrap replications. Non-linear 
functions (BIF=63.4%) more commonly described the relationship between FEV1 percent 
predicted and VAS score (Appendix 5). 
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Table 13. Bootstrap inclusion fractions for variables significantly associated with VAS 
score in final regression model or with bootstrap inclusion fractions > 50% excluded from 
final model, 1000 replications, N=2397 
Variable Bootstrap Inclusion Fraction (%) 
Socio-demographics and medical history  
Gender 77.7 
Race/ethnicity 60.2 
BMI 99.9 
Current work status 100.0 
 
Smoking exposure 
Cigarettes per day (last 30 days) 73.6 
Average alcoholic drinks per week 65.4 
 
Morbidities 
Myocardial infarction 51.7 
Hypercholesterolemia
† 
46.8 
Peripheral vascular disease
† 
46.3 
Arthritis 92.0 
Pulmonary fibrosis* 58.2 
FEV1
 
% predicted 99.5 
  
Symptoms 
Dyspnea 100 
Phlegm 55.6 
Chest pain 91.6 
Poor appetite 96.6 
Fatigued 100.0 
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in one second 
* Pulmonary fibrosis was insignificant in the fully adjusted linear regression model but was 
included in > 50% of bootstrap replications, indicating that it may be an important variable. 
† Hypercholesterolemia and peripheral vascular disease were both significantly 
associated with VAS score but included in < 50% of bootstrap replications 
 
 
4.6 EQ-5D Quality of life dimensions 
The proportion of PanCan participants reporting no problems, some problems or 
severe problems for the EQ-5D (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression) are available in Table 14. While participants commonly reported 
experiencing some problems in any EQ-5D dimension, they were far less likely to report 
severe problems, typical of population based data sets. 
Table 14. Participant distributions of EQ-5D quality of life dimensions 
EQ-5D response 
Mobility 
(N=2526) 
Self-care 
(N=2527) 
Usual 
activities 
(N=2525) 
Pain and 
discomfort 
(N=2526) 
Anxiety and 
depression 
(N=2526) 
No problems 1941 (77%) 2461 (97%) 1973 (78%) 1211 (48%) 1716 (68%) 
      
Some Problems 581 (23%) 58 (2%) 530 (21%) 1248 (49%) 768 (30%) 
      
Severe problems 4 (0.2%) 8 (0.3%) 22 (0.9%) 67 (3%) 42 (2%) 
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4.6.1 Mobility 
Almost 25% of the sample reported experiencing some or severe mobility 
problems (Table 14). Univariate and multivariate logistic regression models are 
presented in Tables 15a, 15b and 15c. Age, education, employment status and BMI 
were significantly associated with mobility in univariate and partially adjusted models. 
The effects of age and education were explained away when exposures, morbidities and 
symptoms were added to the regression model. However, being unemployed 
(ORadjusted=4.52; CI: 1.31 to 15.63; P=0.017), disabled (ORadjusted= 13.76; CI: 7.37 to 
25.69; P<0.001) or on sick leave (ORadjusted=36.03; CI: 18.28 to 71.01; P<0.001) and BMI 
remained significant predictors of mobility (ORadjusted= 1.10; CI: 1.09 to 1.12; P<0.001). 
Multiple exposure variables were significantly associated with mobility in univariate and 
partially adjusted regression models. Only smoking duration remained significant when 
adjusting for all other factors. Increased smoking exposure to cigarettes and marijuana 
was generally associated with increased odds of having some or severe mobility 
problems. Similar to other models, several morbidities and symptoms were univariately 
associated with mobility problems. A total of 4 morbidities, congestive heart failure 
(ORadjusted=3.41; CI: 1.36 to 8.53; P=0.009), hypertension (ORadjusted=1.33; CI: 1.04 to 
1.69; P=0.024), peripheral vascular disease (ORadjusted=1.74; CI: 1.16 to 2.61; P=0.007) 
and arthritis (ORadjusted=2.68, CI: 2.14 to 3.35; P<0.001) were significantly associated 
with experiencing mobility problems. Significant symptoms variables in the final model 
include dyspnea (ORadjusted=1.74; CI: 1.56 to 1.94; P<0.001), poor appetite 
(ORadjusted=1.65; CI: 1.01 to 2.69; P=0.046) and fatigue (ORadjusted=1.68; CI: 1.36 to 2.09; 
P<0.001). Total variation in mobility problems explained by the model was 0.178. The 
Hosmer–Lemeshow goodness of fit test suggests suitable fit, P=0.294. 
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Table 15a. Univariate and adjusted logistic regression odds ratios of variables significantly associated with reporting some or severe 
problems with mobility 
Variable group 
Univariate
 
Partially adjusted*
 
Fully Adjusted 
(N=2406, Pseudo R
2
=0.178)
†
 
Odds ratio (CI; P-value)
‡ 
Odds ratio (CI; P-value)
‡ 
Odds ratio (CI; P-value)
‡ 
Socio-demographics and 
medical history 
 
N=2461, Pseudo R
2
=0.106 
 
Age (years) 1.02 (1.01 to 1.04; 0.006) 1.04 (1.02 to 1.06; <0.001) (P=0.743) 
Education level 0.87 (0.82 to 0.92; <0.001) 0.89 (0.83 to 0.95; <0.001) (P=0.216) 
Employment status    
Employed Referent Referent Referent 
Retired 1.52 (1.23 to 1.88; <0.001) 1.22 (0.97 to 1.53; 0.091) 1.29 (1.02 to 1.64; 0.033) 
Unemployed 3.15 (1.91 to 5.22; <0.001) 3.20 (1.91 to 5.37; <0.001) 2.90 (1.82 to 4.63; <0.001) 
Disabled 11.20 (6.90 to 18.16; <0.001) 12.26 (6.78 to 22.18; <0.001) 8.13 (4.42 to 14.95; <0.001) 
Sick leave 7.93 (2.56 to 24.55; <0.001) 6.89 (1.20 to 39.57; 0.030) 6.71 (1.22 to 36.81; 0.029) 
Other 1.10 (0.62 to 1.94; 0.739) 1.04 (0.45 to 2.39; 0.934) 1.17 (0.51 to 2.65; 0.715) 
    
BMI    
1
st
 term 2.1e
7 
(3729.29 to 1.21e
9
) 1.2e
5 
(48.11 to 3.42e
8
) 1.10 (1.09 to 1.12; <0.001) 
2
nd
 term 4.24e
-25
 (1.5e
-31
 to 1.19e
-18
) 4.47e
-23
 (1.17e
-30 
to 1.7e
-15
) (P=0.111) 
    
Exposures  N=2493, Pseudo R
2
=0.024  
Cigarettes per day (last 30 days) 1.01 (1.01 to 1.02; <0.001) 1.02 (1.01 to 1.02; 0.001) (P=0.585) 
Cigarettes per day (smoking period) 1.02 (1.01 to 1.02; <0.001) 1.02 (1.00 to 1.03; 0.005) (P=0.489) 
Smoking duration (years) 1.04 (1.02 to 1.06; <0.001) 1.05 (1.03 to 1.08; <0.001) 1.04 (1.02 to 1.06; <0.001) 
Time since quitting (years) 0.99 (0.97 to 1.01; 0.399) 1.04 (1.01 to 1.08; 0.021) (P=0.351) 
Marijuana use (joints per month) 1.01 (1.00 to 1.02; 0.008) 1.01 (1.00 to 1.03; 0.009) (P=0.375) 
Abbreviations: BMI, body mass index; CI, confidence interval; N, sample size. 
* Variables eligible for inclusion in preliminary linear regression models are limited to socio-demographics, medical history and exposure 
factors. 
† Logistic regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly 
associated with anxiety/depression in partially adjusted logistic regression models. 
‡ Logistic regression models used to calculate odds ratios, confidence intervals and P-values. 
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Table 15b. Univariate and adjusted logistic regression odds ratios of variables significantly associated with reporting some or severe 
problems with mobility 
Variable group 
Univariate 
 
Partially adjusted* 
 
Fully Adjusted 
(N=2406, Pseudo R
2
=0.178)
† 
 
Odds ratio (CI; P-value)
‡ 
Odds ratio (CI; P-value)
‡
 Odds ratio (CI; P-value)
‡ 
Morbidities  N=2439, Pseudo R
2
=0.098  
Stroke 2.15 (1.31 to 3.51; 0.002) 1.52 (0.99 to 2.34; 0.058) (P=0.108) 
Coronary heart disease 2.17 (1.59 to 2.97; <0.001) 1.32 (1.03 to 1.70; 0.027) (P=0.452) 
Angina 2.52 (1.82 to 3.48; <0.001) 1.83 (1.14 to 2.94; 0.013) (P=0.051) 
Myocardial infarction 1.92 (1.37 to 2.70; <0.001) (P=0.498) Excluded 
Hypercholesterolemia 1.33 (1.10 to 1.60; 0.003) (P=0.637) Excluded 
Hypertension 1.86 (1.54 to 2.24; <0.001) 1.37 (1.13 to 1.68; 0.002) 1.33 (1.04 to 1.69; 0.024) 
Congestive heart failure 2.99 (1.15 to 7.78; 0.025) 2.66 (1.04 to 6.82; 0.041) 3.41 (1.36 to 8.53; 0.009) 
Peripheral vascular disease 2.25 (1.50 to 3.37; <0.001) 1.58 (1.06 to 2.36; 0.026) 1.74 (1.16 to 2.61; 0.007) 
Asthma 1.46 (1.09 to 1.95; 0.011) (P=0.992) Excluded 
Pulmonary fibrosis 1.90 (-0.50 to 4.30; 0.122) 8.18 (1.06 to 63.34; 0.044) (P=0.095) 
Personal cancer history 0.41 (0.06 to 0.76; 0.022) 1.34 (0.91 to 1.97; 0.136) (P=0.107) 
Liver disease 1.53 (1.07 to 2.21; 0.021) 1.55 (1.08 to 2.22; 0.016) (P=0.327) 
Osteoporosis 1.53 (1.21 to 1.95; <0.001) (P=0.270) Excluded 
Diabetes 1.86 (1.39 to 2.49; <0.001) 1.51 (1.24 to 1.83; <0.001) (P=0.655) 
Anemia 1.46 (1.07 to 1.99; 0.017) (P=0.446) Excluded 
Asthma 1.46 (1.09 to 1.95; 0.011) (P=0.992) Excluded 
COPD 1.65 (1.34 to 2.05; <0.001) (P=0.252) Excluded 
Pneumonia 1.61 (1.31 to 1.96; <0.001) 1.30 (1.03 to 1.64; 0.030) (P=0.084) 
Arthritis 3.07 (2.54 to 3.72; <0.001) 3.04 (2.34 to 3.96; <0.001) 2.68 (2.14 to 3.35; <0.001) 
Allergy 1.36 (1.16 to 1.65; 0.002) (P=0.203) Excluded 
FEV1 percent predicted 0.17 (0.10 to 0.28; <0.001) 0.24 (0.14 to 0.43; <0.001) (P=0.054) 
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; N, sample size. 
* Variables eligible for inclusion in preliminary linear regression models are limited to morbidities and symptoms. 
† Logistic regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly associated with 
anxiety/depression in partially adjusted logistic regression models. 
‡ Logistic regression models used to calculate odds ratios, confidence intervals and P-values. 
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Table 15c. Univariate and adjusted logistic regression odds ratios of variables significantly associated with reporting some or severe 
problems with mobility 
 
Variable group 
Univariate 
 
Partially adjusted* 
 
Fully Adjusted 
(N=2406, Pseudo R2=0.178)† 
 
Odds ratio (CI; P-value)‡ Odds ratio (CI; P-value)‡ Odds ratio (CI; P-value)‡ 
Symptoms  N=2507, Pseudo R
2
=0.063  
Dyspnea 2.76 (2.27 to 3.34; <0.001) 2.03 (1.86 to 2.22; <0.001) 1.74 (1.56 to 1.94; <0.001) 
Cough 1.58 (1.31 to 1.91; <0.001) (P=0.983) Excluded 
Phlegm 1.66 (1.38 to 2.00; <0.001) 1.17 (1.03 to 1.32; 0.012) (P=0.433) 
Hemoptysis 1.93 (1.03 to 3.59; 0.039) (P=0.462) Excluded 
Hoarseness 1.46 (1.19 to 1.79; <0.001) (P=0.758) Excluded 
Wheeze 2.02 (1.68 to 2.44; <0.001) 1.28 (1.00 to 1.64; 0.047) (P=0.532) 
Chest pain 1.37 (1.09 to 1.73; 0.008) 0.85 (0.64 to 1.06; 0.125) (P=0.278) 
Poor appetite 2.10 (1.54 to 2.87; <0.001) 1.35 (0.95 to 1.92; 0.092) 1.65 (1.01 to 2.69; 0.046) 
Fatigued 2.41 (1.99 to 2.91; <0.001) 1.76 (1.32 to 2.34; <0.001) 1.68 (1.36 to 2.09; <0.001) 
Abbreviations: CI, confidence interval; N, sample size. 
* Variables eligible for inclusion in preliminary linear regression models are limited to morbidities factors. 
† Logistic regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly 
associated with anxiety/depression in partially adjusted logistic regression models. 
‡ Logistic regression models used to calculate odds ratios, confidence intervals and P-values. 
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4.6.2 Self-care 
The large majority of participants (97%) reported no problems with self-care 
(Table 14). Univariate and multivariable logistic regression models for self-care are 
presented in Table 16a and Table 16b. Educational achievement and employment status 
were the only socio-demographic variables significantly associated with self-care. 
Increased exposure to both smoking and alcohol were also associated with higher odds 
of reporting some or severe problems with self-care. Their insignificance in the fully 
adjusted model indicates an upstream association may be present, with the effects of 
smoking and alcohol consumption mediating the relationship. Univariate analysis 
revealed several significant morbidities and symptoms. However only two morbidities, 
having an allergy (ORadjusted=1.79; CI: 1.12 to 2.87; P=0.015) and FEV1 percent predicted 
(ORadjusted=0.15; CI: 0.04 to 0.51; P=0.002), and one symptom, fatigue (ORadjusted=2.70; 
CI: 1.41 to 5.15; P=0.003) remained significant in the fully adjusted model. The 
independent variables explained 0.172 of the variation in self-care. The Hosmer–
Lemeshow goodness-of-fit test suggests good model fit (P=0.909).  
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Table 16a. Univariate and adjusted logistic regression odds ratios of variables significantly associated with reporting some or severe 
problems with self-care 
Variable group 
Univariate
 
Partially adjusted*
 
Fully Adjusted 
(N=2464, Pseudo R2=0.172)†
 
Odds ratio (CI; P-value)‡ Odds ratio (CI; P-value)‡ Odds ratio (CI; P-value)‡ 
Socio-demographics and 
medical history 
 
N=2461, Pseudo R2=0.131 
 
Education level 0.82 (0.71 to 0.95; 0.010) 0.85 (0.72 to 1.01; 0.067) (P=0.260) 
Employment status    
Employed Referent Referent Referent 
Retired 1.43 (0.71 to 2.89; 0.316) 1.32 (0.73 to 2.42; 0.361) 1.46 (0.86 to 2.46; 0.157) 
Unemployed 5.89 (2.02 to 17.21; 0.001) 5.46 (1.64 to 18.20; 0.006) 4.52 (1.31 to 15.63; 0.017) 
Disabled 20.29 (9.40 to 43.82; <0.001) 18.35 (8.76 to 38.46; <0.001) 13.76 (7.37 to 25.68; <0.001) 
Sick leave 35.07 (9.48 to 129.76; <0.001) 23.68 (9.38 to 59.79; <0.001) 36.03 (18.28 to 71.01; <0.001) 
Other 2.79 (0.77 to 10.06; 0.118) 1.03 (-0.16 to 2.23; 0.090) 2.74 (0.77 to 9.76; 0.117) 
    
Exposures  N=2494, Pseudo R2=0.027  
Cigarettes per day (last 30 days) 1.03 (1.02 to 1.05; <0.001) 1.03 (1.01 to 1.04; 0.001) (P=0.333) 
Alcoholic drinks per week 1.01 (1.00 to 1.02; 0.002) 1.01 (1.00 to 1.02; 0.007) (P=0.093) 
Abbreviations: CI, confidence interval; N, sample size. 
* Variables eligible for inclusion in preliminary linear regression models are limited to socio-demographics, medical history and exposure 
factors. 
† Logistic regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly 
associated with anxiety/depression in partially adjusted logistic regression models. 
‡ Logistic regression models used to calculate odds ratios, confidence intervals and P-values. 
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Table 16b. Univariate and adjusted logistic regression odds ratios of variables significantly associated with reporting some or severe 
problems with self-care 
Variable group 
Univariate 
 
Partially adjusted* 
 
Fully Adjusted 
(N=2464, Pseudo R2=0.172)† 
 
Odds ratio (CI; P-value)‡ Odds ratio (CI; P-value)‡ Odds ratio (CI; P-value)‡ 
Morbidities  N=2440, Pseudo R2=0.060  
Peripheral vascular disease 2.44 (1.03 to 5.79; 0.043) 2.02 (0.79 to 5.15; 0.142) (P=0.319) 
Asthma 2.66 (1.45 to 4.89; 0.002) (P=0.642) Excluded 
COPD 2.76 (1.67 to 4.56; <0.001) 1.92 (0.80 to 4.62; 0.144) (P=0.254) 
Pneumonia 1.62 (0.97 to 2.70; 0.065) (P=0.692) Excluded 
Arthritis 1.86 (1.13 to 3.05; 0.014) (P=0.298) Excluded 
Allergy 2.07 (1.26 to 3.39; 0.004) 1.78 (0.98 to 3.21; 0.057) 1.79 (1.12 to 2.87; 0.015) 
FEV1 percent predicted 0.09 (0.03 to 0.32; <0.001) (0.08 to 0.39; <0.001) 0.15 (0.04 to 0.51; 0.002) 
    
Symptoms  N=2508, Pseudo R2=0.063  
Dyspnea 2.42 (1.44 to 4.07; 0.001) (P=0.413) Excluded 
Phlegm 1.77 (1.07 to 2.93; 0.026) (P=0.685) Excluded 
Hemoptysis 3.96 (1.37 to 11.41; 0.011) (P=0.254) Excluded 
Hoarseness 1.96 (1.19 to 3.25; 0.009) (P=0.296) Excluded 
Wheeze 2.39 (1.45 to 3.95; 0.001) 1.70 (0.97 to 2.97; 0.062) (P=0.219) 
Chest pain 1.87 (1.08 to 3.26; 0.026) (P=0.721) Excluded 
Poor appetite 3.20 (1.71 to 5.98; <0.001) 1.85 (0.80 to 4.24; 0.148) (P=0.314) 
Fatigue 3.88 (2.26 to 6.65; <0.001) 3.01 (1.36 to 6.69; 0.007) 2.69 (1.41 to 5.13; 0.003) 
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; N, sample 
size. 
* Variables eligible for inclusion in preliminary linear regression models are limited to socio-demographics, medical history and exposure 
factors. 
† Logistic regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly 
associated with anxiety/depression in partially adjusted logistic regression models. 
‡ Logistic regression models used to calculate odds ratios, confidence intervals and P-values. 
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4.6.3 Usual activities 
 
Almost 80% of the sample did not have any problems completing usual activities 
(Table 14). Odds ratios for variables associated with experiencing problems completing 
usual activities are reported in Tables 17a and 17b. With exception to being white and 
having a familial history of cancer, all socio-demographic variables were significantly 
associated with problems completing usual activities in univariate analysis. The effects 
of age, gender and education were explained away after further adjustment. In the fully 
adjusted model, compared to those who are employed, retired, unemployed and 
participants on sick leave were all more likely to report problems completing usual 
activities. A non-linear relationship between BMI and problems completing usual 
activities was also apparent in the fully adjusted model.  
Multiple exposures were significantly associated with increased odds of reporting 
some or severe problems completing usual activities in univariate and partially adjusted 
analysis. However, after full adjustment no independent associations between exposure 
variables and usual activities were identified. 
Several morbidities and symptoms were significantly associated with problems 
completing usual activities in all regression models. Despite 15 morbidities having a 
univariate association with problems completing usual activities, only arthritis remained 
significant in the fully adjusted model; (ORadjusted=1.99; CI: 1.70 to 2.33; P<0.001). The 
partially adjusted symptoms model explained more variation in completing usual 
activities than any other domain (Pseudo R2=0.1055). The fully adjusted model revealed 
three symptoms with downstream associations; dyspnea (ORadjusted=2.13; CI: 1.88 to 
2.42; P<0.001), poor appetite (ORadjusted=2.17; CI: 1.26 to 3.73; P=0.005) and fatigue 
(ORadjusted=2.35; CI: 1.76 to 3.16; P<0.001). The pseudo R
2 for the fully adjusted model is 
0.190. Hosmer–Lemeshow goodness of fit test (P=0.663) suggests good model fit.
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Table 17a. Univariate and adjusted logistic regression odds ratios of variables significantly associated with experiencing some or 
severe problems with completing usual activities 
Variable group 
Univariate
 
Partially adjusted*
 
Fully Adjusted
† 
(N= 2423, Pseudo R
2
=0.196)
 
Odds ratio (CI; P-value)
‡
 Odds ratio (CI; P-value)
‡
 Odds ratio (CI; P-value)
‡ 
Socio-demographics and 
medical history 
 
N=2459, Pseudo R
2
=0.106 
 
Age (years)    
1
st
 term 0.92 (0.87 to 0.97; 0.001)
§ 
(P=0.227) Excluded 
2
nd
 term 1.04 (1.02 to 1.07; 0.001)
§
   
Gender (male vs. female) 0.76 (0.63 to 0.92; 0.005) 0.78 (0.59 to 1.02; 0.070) (P=0.521) 
Education level 0.86 (0.82 to 0.91; <0.001) 0.91 (0.86 to 0.96; <0.001) (P=0.477) 
Employment status    
Employed Referent Referent Referent 
Retired 1.30 (1.04 to 1.61; 0.020) 1.26 (1.05 to 1.51; 0.012) 1.40 (1.12 to 1.76; 0.003) 
Unemployed 4.14 (2.52 to 6.80; <0.001) 3.76 (2.43 to 5.81; <0.001) 3.41 (2.12 to 5.50; <0.001) 
Disabled 21.64 (12.40 to 37.74; <0.001) 21.04 (11.02 to 40.19; <0.001) 16.62 (9.05 to 30.5; <0.001) 
Sick leave 28.49 (6.25 to 129.81; <0.001) 25.33 (6.44 to 99.63; <0.001) 29.25 (8.45 to 101.28; <0.001) 
Other 1.15 (0.65 to 2.03; 0.627) 1.14 (0.60 to 2.15; 0.688) 1.33 (0.63 to 2.77; 0.452) 
BMI    
1
st
 term 1.72e
15
 (9.20e
10
 to 3.23e
19
; <0.001)
║
 3.04e
12
 (3.1e
6
 to 3.01e
18
; <0.001)
¶ 
1.02 (1.01 to 1.03; <0.001)** 
2
nd
 term 3.31e
-17
 (2.09e
-21
 to 5.23e
-13
; <0.001)
║
 8.34e
-15 
(3.1e
-20
 to 2.24e
-9
; <0.001)
¶ 
 
    
Exposures  N=2493, Pseudo R
2
=0.016  
Cigarettes per day (last 30 days) 1.04 (1.02 to 1.06; <0.001) 1.01 (1.01 to 1.02; <0.001) (P=0.517) 
Cigarettes per day (smoking period) 1.02 (1.01 to 1.03; <0.001) 1.02 (1.00 to 1.02; <0.001) (P=0.635) 
Time since quitting (years) 0.97 (0.95 to 1.00; 0.047) (P=0.361) Excluded 
Alcoholic drinks per week 1.004 (1.00 to 1.01; 0.031) (P=0.711) Excluded 
Marijuana use (joints per month) 1.01 (1.00 to 1.02; 0.006) 1.01 (1.00 to 1.02; 0.030) (P=0.593) 
Abbreviations: BMI, body mass index; CI, confidence interval; N, sample size. 
* Variables eligible for inclusion in preliminary linear regression models are limited to socio-demographic and medical history, or exposure variables. 
† Logistic regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly associated with 
anxiety/depression in partially adjusted logistic regression models. 
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‡ Logistic regression models used to calculate odds ratios, confidence intervals and P-values. 
§ Age has a non-linear association with usual activities and is described by the following terms; 
 𝑇𝑒𝑟𝑚 1 = [(
𝑎𝑔𝑒
10
)
3
− 238.328] ∗ 0.9159611 
𝑇𝑒𝑟𝑚 2 = [(
𝑎𝑔𝑒
10
)
3
∗ 𝑙𝑛 (
𝑎𝑔𝑒
10
) − 434.8411837] ∗ 1.040678  
║BMI has a non-linear relationship with usual activities and is described by the following terms; 
𝑇𝑒𝑟𝑚 1 = [(
𝐵𝑀𝐼
10
)
−2
− 0.1418960034] ∗ 1.72e15 
𝑇𝑒𝑟𝑚 2 = [(
𝐵𝑀𝐼
10
)
−0.5
− 0.6137514637] ∗ 3.31e-17 
¶ BMI has a non-linear relationship with usual activities and is described by the following terms;  
𝑇𝑒𝑟𝑚 1 = [(
𝐵𝑀𝐼
10
)
−2
− .1371742112] * 3.04e12 
Term 2 = [(
𝐵𝑀𝐼
10
)
−0.5
− 0.6085806195] ∗ 8.34e-15 
** BMI has a non-linear relationship with usual activities and is described by the following term;  
𝑇𝑒𝑟𝑚 1 = [(
BMI
10
)
3
− 18.712593543] ∗ 1.020124 
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Table 17b. Univariate and adjusted logistic regression odds ratios of variables significantly associated with reporting some or severe 
problems with completing usual activities 
Variable group 
Univariate 
 
Partially adjusted* 
 
Fully Adjusted 
(N=2423, Pseudo R
2
=0.196)
† 
 
Odds ratio (CI; P-value)
‡
 Odds ratio (CI; P-value)
‡
 Odds ratio (CI; P-value)
‡ 
Morbidities  N=2444, Pseudo R
2
= 0.08  
Stroke 1.91 (1.16 to 3.17; 0.011) 1.46 (0.97 to 2.21; 0.073) (P=0.173) 
CHD 1.41 (1.01 to 1.98; 0.046) (P=0.928) Excluded 
Angina 1.83 (1.31 to 2.57; <0.001) 1.58 (1.17 to 2.14; 0.003) (P=0.160) 
Hypertension 1.54 (1.27 to 1.87; <0.001) 1.22 (1.01 to 1.48; 0.037) (P=0.078) 
PVD 1.56 (1.01 to 2.40; 0.043) (P=0.360) Excluded 
Asthma 1.81 (1.36 to 2.42; <0.001) (P=0.960) Excluded 
COPD 2.35 (1.90 to 2.90; <0.001) 1.61 (1.35 to 1.91; <0.001) (P=0.505) 
Pneumonia 1.72 (1.41 to 2.11; <0.001) 1.27 (1.03 to 1.55; 0.024) (P=0.212) 
Liver disease 1.74 (1.21 to 2.51; 0.003) 1.60 (1.18 to 2.17; 0.002) (P=0.209) 
Osteoporosis 1.54 (1.20 to 1.96; 0.001) (P=0.319) Excluded 
Arthritis 2.42 (2.00 to 2.93; <0.001) 2.18 (1.80 to 2.65; <0.001) 1.94 (1.65 to 2.29; <0.001) 
Allergy 1.70 (1.39 to 2.06; <0.001) 1.41 (1.16 to 1.72; 0.001) 1.38 (1.11 to 1.73; 0.004) 
Diabetes 1.54 (1.14 to 2.09; 0.005) (P=0.215) Excluded 
Anemia 1.80 (1.32 to 2.44; <0.001) 1.42 (1.05 to 1.92; 0.024) (P=0.156) 
FEV1 percent predicted 0.13 (0.08 to 0.22; <0.001) 0.22 (0.14 to 0.36; <0.001) 0.32 (0.15 to 0.68; 0.003) 
    
Symptoms  N=2506, Pseudo R
2
= 0.113  
Dyspnea 3.55 (2.90 to 4.35; <0.001) 2.19 (1.87 to 2.57; <0.001) 1.90 (1.60 to 2.24; <0.001) 
Cough 1.59 (1.31 to 1.93; <0.001) 0.79 (0.60 to 1.05; 0.099) (P=0.590) 
Phlegm 1.95 (1.61 to 2.37; <0.001) 1.39 (1.11 to 1.75; 0.004) (P=0.068) 
Hoarseness 1.99 (1.62 to 2.44; <0.001) 1.30 (1.08 to 1.55; 0.006) (P=0.149) 
Wheeze 2.24 (1.85 to 2.72; <0.001) 1.21 (0.98 to 1.51; 0.078) (P=0.612) 
Chest pain 1.77 (1.41 to 2.23; <0.001) (P=0.599) Excluded 
Poor appetite 3.71 (2.74 to 5.02; <0.001) 2.11 (1.41 to 3.17; <0.001) 2.37 (1.52 to 3.70; <0.001) 
Fatigued 3.71 (3.04 to 4.52; <0.001) 2.50 (1.85 to 3.38; <0.001) 2.31 (1.71 to 3.11; <0.001) 
Abbreviations: CHD, coronary heart disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one 
second; N, sample size; PVD, peripheral vascular disease. 
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* Variables eligible for inclusion in preliminary linear regression models are limited to morbidities or symptoms. 
† Logistic regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly associated with 
anxiety/depression in partially adjusted logistic regression models. 
‡ Logistic regression models used to calculate odds ratios, confidence intervals and P-values. 
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4.6.4 Pain and Discomfort 
Of the 2,526 participants providing data for this dimension, 1,315 (52.1%) 
experienced some or severe pain or discomfort (Table 14). Table 18a and 18b detail 
regression results for variables significantly associated with experiencing pain and 
discomfort. Males were less likely to report pain and discomfort problems in preliminary 
regression models but the association was explained away after full adjustment. 
Participants with higher educational achievement were less likely to experience pain or 
discomfort in all models. In all models, retired, unemployed and disabled participants 
were significantly more likely to report experiencing pain or discomfort than the 
employed. A positive linear relationship between increased BMI and higher odds of 
experiencing pain and discomfort was present in univariate and adjusted analysis. 
Individuals with a heavier smoking history, as measured by cigarettes smoked in 
the last 30 days or during the life-time smoking period and by smoking duration (Table 
20), were significantly more likely to report some or severe pain. All significant exposure 
associations were explained away after full adjustment. Compared to all other domains, 
exposures explained the least variation in pain and discomfort (Pseudo R2=0.0072). In 
univariate analysis, all measured morbidities except for anemia were associated with 
significantly greater odds of some or severe pain, however in the fully adjusted model, 
only arthritis (ORadjusted=3.36, CI: 2.80 to 4.03; P<0.001) remained significant. In 
univariate analysis, all measured symptoms were associated with significantly increased 
odds of some or severe pain. Significantly associated symptoms in the full regression 
model include dyspnea (ORadjusted=1.28; CI: 1.02 to 1.60; P=0.033), chest pain 
(ORadjusted=1.63; CI: 1.18 to 2.25; P=0.003), poor appetite (ORadjusted=1.60; CI: 1.21 to 
2.11; P=0.001) and fatigue (ORadjusted=1.68; CI: 1.39 to 2.04; P<0.001). The final model 
explained 0.142 of the variation in pain or discomfort. The Hosmer–Lemeshow goodness 
of fit test (P=0.501), suggests good model fit.
75 
 
Table 18a. Univariate and adjusted logistic regression odds ratios of variables significantly associated with reporting some or severe 
problems with pain or discomfort 
Variable group 
Univariate
 
Partially adjusted*
 
Fully Adjusted 
(N=2406, Pseudo R
2
= 0.139)
†
 
Odds ratio (CI; P-value)
‡ 
Odds ratio (CI; P-value)
‡ 
Odds ratio (CI; P-value)
‡ 
Socio-demographics and 
medical history 
 
N=2460, Pseudo R
2
= 0.041 
 
Gender (male vs. female) 0.80 (0.68 to 0.93; 0.005) 0.78 (0.67 to 0.92; 0.003) (P=0.297) 
Education level 0.84 (0.80 to 0.88; <0.001) 0.86 (0.80 to 0.92; <0.001) 0.88 (0.82 to 0.95; 0.001) 
Employment status    
Employed Referent Referent Referent 
Retired 1.27 (1.07 to 1.49; 0.006) 1.25 (1.10 to 1.41; <0.001) 1.26 (1.10 to 1.40; <0.001) 
Unemployed 2.02 (1.23 to 3.33; 0.005) 1.82 (1.30 to 2.55; <0.001) (P=0.058) 
Disabled 8.02 (4.21 to 15.27; <0.001) 6.99 (2.91 to 16.75; <0.001) 4.57 (2.03 to 10.3; <0.001) 
Sick leave 3.81 (1.04 to 14.0; 0.043) 3.24 (0.75 to 14.0; 0.116) (P=0.169) 
Other 1.09 (0.71 to 1.69; 0.685) 1.08 (0.77 to 1.51; 0.674) (P=0.550) 
BMI 1.05 (1.03 to 1.06; <0.001) 1.05 (1.04 to 1.06; <0.001) 1.03 (1.02 to 1.05; <0.001) 
    
Exposures  N=2493, Pseudo R
2
= 0.009  
Cigarettes per day (last 30 days) 1.01 (1.01 to 1.02; <0.001) 1.02 (1.01 to 1.02; <0.001) (P=0.423) 
Cigarettes per day (smoking period) 1.01 (1.00 to 1.02; 0.006) (P=0.224) Excluded 
Smoking duration (years) 1.01 (1.00 to 1.03; 0.038) 1.02 (1.00 to 1.03; 0.025) (P=0.561) 
Time since quitting (years) 0.99 (0.97 to 1.01; 0.295) 1.03 (1.01 to 1.05; 0.008) (P=0.750) 
Alcoholic drinks per week 7.27e
-8
 (2.44e
-8
 to 1.21e
-7
; 0.003)
§ 
1.0002 (1.0001 to 1.0004; <0.001)
║
  (P=0.842) 
Abbreviations: BMI, body mass index; CI, confidence interval; N, sample size. 
* Variables eligible for inclusion in preliminary linear regression models are limited to socio-demographic and medical history, or exposure factors. 
† Logistic regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly associated with 
anxiety/depression in partially adjusted logistic regression models. 
‡ Logistic regression models used to calculate odds ratios, confidence intervals and P-values. 
§ Alcoholic drinks per week has a non-linear association with experiencing pain or discomfort, and is described by the following term; 
𝑇𝑒𝑟𝑚 1 = {(𝑎𝑙𝑐𝑜ℎ𝑜𝑙 + 0.0999999940395355)/100)−1 − 6.211180127} ∗  1.000263 
║ Alcoholic drinks per week has a non-linear association with experiencing pain or discomfort, and is described by the following term;  
𝑇𝑒𝑟𝑚 1 = {(𝑎𝑙𝑐𝑜ℎ𝑜𝑙 + 0.0999999940395355)/100)−2 − 39.07149013} ∗  7.27𝑒−8 
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Table 18b. Univariate and adjusted logistic regression odds ratios of variables significantly associated with reporting some or severe 
problems with pain or discomfort 
Variable group 
Univariate 
 
Partially adjusted* 
 
Fully Adjusted 
(N=2406, Pseudo R
2
= 0.139)
† 
 
Odds ratio (CI; P-value)
‡ 
Odds ratio (CI; P-value)
‡ 
Odds ratio (CI; P-value)
‡ 
Morbidities  N=2444, Pseudo R
2
= 0.091  
CHD 1.46 (1.08 to 1.98; 0.015) (P=0.424) Excluded 
Angina 1.68 (1.21 to 2.32; 0.002) 1.42 (0.92 to 2.18; 0.114) (P=0.185) 
Hypercholesterolemia 1.35 (1.15 to 1.58; <0.001) 1.20 (1.11 to 1.31; <0.001) 1.21 (1.08 to 1.36; 0.001) 
Hypertension 1.46 (1.24 to 1.72; <0.001) (P=0.207) Excluded 
Asthma 1.47 (1.12 to 1.92; 0.005) (P=0.840) Excluded 
COPD 1.55 (1.27 to 1.88; <0.001) 1.22 (0.99 to 1.51; 0.067) (P=0.781) 
Pneumonia 1.57 (1.31 to 1.87; <0.001) 1.29 (1.06 to 1.56; 0.012) (P=0.117) 
Osteoporosis 1.62 (1.30 to 2.02; <0.001) 1.27 (0.99 to 1.63; 0.057) (P=0.127) 
Arthritis 3.83 (3.23 to 4.55; <0.001) 3.66 (2.95 to 4.53; <0.001) 3.32 (2.74 to 4.01; <0.001) 
Allergy 1.35 (1.14 to 1.61; <0.001) (P=0.307) Excluded 
Diabetes 1.65 (1.24 to 2.18; 0.001) 1.41 (0.95 to 2.09; 0.089) (P=0.112) 
Anemia 1.39 (1.05 to 1.85; 0.023) (P=0.712) Excluded 
FEV1 percent predicted 0.40 (0.26 to 0.62; <0.001) 0.58 (0.34 to 0.98; 0.033) (P=0.632) 
    
Symptoms  N=2507, Pseudo R
2
= 0.057  
Dyspnea 2.24 (1.91 to 2.63; <0.001) 1.48 (1.18 to 1.85; 0.001) 1.31 (1.05 to 1.64; 0.016) 
Cough 1.38 (1.18 to 1.62; <0.001) 0.87 (0.74 to 1.02; 0.080) (P=0.503) 
Phlegm 1.56 (1.34 to 1.83; <0.001) 1.24 (1.00 to 1.53; 0.047) (P=0.521) 
Hoarseness 1.62 (1.35 to 1.94; <0.001) 1.17 (1.02 to 1.35; 0.023) (P=0.575) 
Wheeze 1.89 (1.61 to 2.23; <0.001) 1.27 (1.05 to 1.53; 0.013)  (P=0.110) 
Chest pain 2.19 (1.76 to 2.73; <0.001) 1.49 (1.17 to 1.91; 0.001) 1.61 (1.17 to 2.23; 0.004) 
Poor appetite 2.25 (1.63 to 3.09; <0.001) 1.35 (1.14 to 1.61; 0.001) 1.49 (1.14 to 1.95; 0.004) 
Fatigued 2.49 (2.11 to 2.94; <0.001) 1.84 (1.51 to 2.24; <0.001) 1.70 (1.41 to 2.03; <0.001) 
Weight loss 1.44 (1.09 to 1.92; 0.011) (P=0.524) Excluded 
Abbreviations: CHD, coronary heart disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one 
second; N, sample size. 
* Variables eligible for inclusion in preliminary linear regression models are limited to morbidities and symptoms factors. 
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† Logistic regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly associated with 
anxiety/depression in partially adjusted logistic regression models. 
‡ Logistic regression models used to calculate odds ratios, confidence intervals and P-values. 
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4.6.5 Anxiety or depression 
A total of 2526 participants provided anxiety/depression domain level quality of 
life scores. Approximately two-thirds of the sample reported having no anxiety or 
depression problems (Table 14). Variables significantly associated with experiencing 
some or severe problems with anxiety or depression are described in Tables19a and 
Table 19b. Socio-demographic and symptom variables explained the greatest amount of 
variation in experiencing anxiety or depression. Odds of experiencing anxiety or 
depression decreased among older participants. However, these effects were explained 
away as other variables were added to the regression model. In all regression models 
females were almost twice as likely to experience problems with anxiety or depression. 
Participants with higher educational achievement were less likely to experience anxiety 
or depression. Retirees did not significantly differ compared to employed participants. 
However, unemployed (ORadjusted=2.25; CI: 1.22 to 4.15; P=0.009), disabled 
(ORadjusted=3.84; CI: 2.44 to 6.03; P<0.001) and individuals on sick leave (ORadjusted=6.67; 
CI: 2.66 to 16.7; P<0.001) were all significantly more likely to experience some or severe 
problems. 
Of all partially adjusted regression models from each variable group, exposures 
explained the least variation in experiencing anxiety or depression (Pseudo R2=0.008). 
Adjusting for other exposure factors, increased time since quitting smoking and reduced 
alcohol consumption were both associated with increased odds of reporting no problems 
with anxiety or depression. After full adjustment no exposures were independently 
associated with anxiety or depression. Several morbidities were significantly associated 
with increased odds of reporting some or severe problems with anxiety or depression in 
univariate and partially adjusted regression models. However, only the effect of arthritis 
(ORadjusted=1.24; CI: 1.04 to 1.46; P=0.014) remained significant after adjustment for 
socio-demographic, exposure and symptom variables. Almost all symptoms were 
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significantly associated with increased odds of anxiety or depression in univariate 
analysis. Half of the symptoms remained significant in the partially adjusted regression 
model and one third were associated with increased odds of experiencing anxiety or 
depression in the fully adjusted model. Having a poor appetite (ORadjusted=2.51; CI: 1.73 
to 3.63; P<0.001) and feeling fatigued (ORadjusted=2.31; CI: 2.03 to 2.62; P<0.001) were 
symptoms most highly associated with experiencing anxiety or depression. The final 
regression model explained 0.114 of the total variation in experiencing anxiety or 
depression. Hosmer–Lemeshow goodness of fit test (P=0.490) suggests good model fit. 
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Table 19a. Univariate and adjusted logistic regression odds ratios of variables significantly associated with reporting some or severe 
problems with anxiety or depression 
Variable group 
Univariate 
 
Partially adjusted* 
 
Fully Adjusted 
(N=2493, Pseudo R
2
=0.114)
† 
 
Odds ratio (CI; P-value)
‡ 
Odds ratio (CI; P-value)
‡
 Odds ratio (CI; P-value)
‡ 
Socio-demographics and 
medical history 
 
N=2460, Pseudo R
2
=0.051 
 
Age (years) 0.97 (0.95 to 0.98; <0.001) (P=0.234) Excluded 
Gender (male vs. female) 0.54 (0.46 to 0.64; <0.001) 0.52 (0.43 to 0.64; <0.001) 0.56 (0.45 to 0.71; <0.001) 
Education 0.89 (0.85 to 0.94; <0.001) 0.92 (0.87 to 0.98; 0.010) (P=0.136) 
Employment status    
Employed Referent Referent Referent 
Retired 1.00 (0.83 to 1.20; 0.967) 0.96 (0.83 to 1.12; 0.616) 1.03 (0.88 to 1.20; 0.729) 
Unemployed 3.18 (1.95 to 5.17; <0.001) 2.93 (1.78 to 4.83; <0.001) 2.25 (1.22 to 4.15; 0.009) 
Disabled 5.42 (3.38 to 8.71; <0.001) 5.29 (3.23 to 8.65; <0.001) 3.84 (2.44 to 6.03; <0.001) 
Sick leave 5.40 (1.65 to 17.68; 0.005) 7.81 (3.04 to 20.07; <0.001) 6.67 (2.66 to 16.7; <0.001) 
Other 1.18 (0.74 to 1.88; 0.486) 1.09 (0.68 to 1.75; 0.714) 1.15 (0.57 to 2.31; 0.691) 
Family history of cancer 1.36 (1.14 to 1.62; 0.001) 1.21 (0.91 to 1.60; 0.187) (0.166) 
    
Exposures  N=2493, Pseudo R
2
=0.008  
Cigarettes per day (last 30 days) 1.01 (1.01 to 1.02; <0.001) (P=0.267) Excluded 
Smoking duration (years) 0.98 (0.97 to 1.00; 0.013) 0.97 (0.96 to 0.98; <0.001) (P=0.676) 
Time since quitting (years) 0.97 (0.95 to 0.99; 0.004) 0.96 (0.92 to 0.99; 0.017) (P=0.194) 
Alcoholic drinks per week 1.00 (1.00 to 1.01; 0.061) 1.00 (1.00 to 1.01; 0.036) (P=0.196) 
Marijuana use (joints per month) 0.95 (0.92 to 0.98; <0.001)
§ 
(P=0.234) Excluded 
Abbreviations: CI, confidence interval; N, sample size. 
* Variables eligible for inclusion in preliminary linear regression models are limited to socio-demographic and medical history, or exposure variables. 
† Logistic regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly associated with 
anxiety/depression in partially adjusted logistic regression models. 
‡ Beta-coefficients, confidence intervals and p-values calculated using logistic regression models. 
§ Average weekly marijuana use has a non-linear relationship with anxiety/depression and is described by the following term; 
                                                                                     𝑇𝑒𝑟𝑚 1 = {[
𝑚𝑎𝑟𝑖𝑗𝑢𝑎𝑛𝑎 𝑢𝑠𝑒+1
100
]
−0.5
− 4.472135955} ∗ 0.9499725 
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Table 19b. Univariate and adjusted logistic regression odds ratios of variables significantly associated with reporting some or severe 
problems with anxiety or depression 
Variable group 
Univariate 
 
Partially adjusted* 
 
Fully Adjusted
 
(N=2493, Pseudo R
2
=0.114)
†
 
 
Odds ratio (CI; P-value)
‡ 
Odds ratio (CI; P-value)
‡ 
Odds ratio (CI; P-value)
‡ 
Morbidities  N=2444, Pseudo R
2
=0.024  
Asthma 1.25 (0.95 to 1.65; 0.110) (P=0.876) Excluded 
COPD 1.59 (1.30 to 1.94; <0.001) 1.41 (1.09 to 1.82; 0.009) (P=0.388) 
Pneumonia 1.57 (1.30 to 1.88; <0.001) 1.39 (1.16 to 1.66; <0.001) (P=0.150) 
Osteoporosis 1.46 (1.17 to 1.82; 0.001) 1.22 (0.94 to 1.54; 0.110) (P=0.260) 
Arthritis 1.56 (1.32 to 1.85; <0.001) 1.44 (1.20 to 1.73; <0.001) 1.24 (1.04 to 1.46; 0.014) 
Anemia 1.86 (1.40 to 2.47; <0.001) 1.63 (1.28 to 2.06; <0.001) (P=0.110) 
Blood disease 1.75 (0.99 to 3.09; 0.054) 1.57 (1.15 to 2.14; 0.004) (P=0.522) 
FEV1 percent predicted 0.64 (0.40 to 1.00; 0.050) (P=0.490) Excluded 
    
Symptoms  N=2507, Pseudo R
2
=0.086  
Dyspnea 2.32 (1.95 to 1.75; <0.001) 1.63 (1.32 to 2.01; <0.001) 1.44 (1.21 to 1.72; <0.001) 
Cough 1.15 (0.98 to 1.36; 0.094) 0.76 (0.61 to 0.95; 0.017) (P=0.498) 
Phlegm 1.27 (1.08 to 1.50; 0.005) (P=0.774) Excluded 
Hemoptysis 1.78 (0.98 to 3.24; 0.059) (P=0.706) Excluded 
Hoarseness 1.53 (1.27 to 1.84; <0.001) (P=0.372) Excluded 
Wheeze 1.57 (1.32 to 1.86; <0.001) (P=0.836) Excluded 
Chest pain 2.10 (1.70 to 2.59; <0.001) 1.36 (1.04 to 1.79; 0.026) (P=0.104) 
Poor appetite 4.44 (3.25 to 6.05; <0.001) 2.79 (1.92 to 4.06; <0.001) 2.51 (1.73 to 3.63; <0.001) 
Fatigued 3.33 (2.79 to 3.96; <0.001) 2.53 (2.28 to 2.81; <0.001) 2.31 (2.03 to 2.62; <0.001) 
Weight loss 1.48 (1.11 to 1.97; 0.007) (P=0.588) Excluded 
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; N, sample size. 
* Variables eligible for inclusion in preliminary linear regression models are limited to morbidities or symptoms variables. 
† Logistic regression model contains socio-demographic, smoking/alcohol exposures, morbidities and symptoms which were significantly associated with 
anxiety/depression in partially adjusted logistic regression models. 
‡ Logistic regression models used to calculate odds ratios, confidence intervals and P-values. 
82 
 
4.7 Background to the resultant models  
Assumptions verified when conducting linear regression are described below.144 
4.7.1 Assumption 1.Linear relationship between independent and dependent variables 
As previously discussed, the MFP selection procedure allows for identification of 
independent variables which have a non-linear relationship with the dependent variable. 
4.7.2 Assumption 2. Independence of observations 
 
This assumption requires that all predictor variables be independent of one 
another, that the results of one participant do not affect the results of others. All 
participants completed study questionnaires independently and without knowledge of 
study results. However, modelling used cluster analysis to handle sampling by study 
sites, which is recommended when correlation of observations is expected within 
specific groups of the sample. Observations must still be independent between 
clusters.153 Cluster analysis produces robust standard errors which compensate for 
clustering of data within subsets of the sample. Regarding PanCan data, it was possible 
that participants from the same study site, experiencing similar location specific 
exposures, would report VAS scores which were correlated with one another. Univariate 
and adjusted analyses revealed significant relationships between study site and VAS 
score. Cluster adjustment was applied to regression analyses to account for potential 
differences in HRQoL due to sampling of study participants in different study sites.  
4.7.3 Assumption 3. Normality 
 
VAS score, which should follow a normal distribution, is slightly skewed left with 
the upper tail being cut off since it is impossible for VAS scores to exceed 100 (Figure 
12). Of multiple transformations, square and cubic transformations most closely 
resembled a normal distribution; however, negative kurtosis was present in both 
(Appendix 6). This assumption violation might typically be concerning. However, 
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according to Lumley et al. (2002), the normality assumption is unnecessary for large 
data sets, such as the PanCan, due to the central limit theorem.154 Therefore, the 
original untransformed VAS score was utilized. Bootstrap analysis was conducted to 
assess stability of the final model. 
 
 
Figure 11. Histogram of PanCan Visual Analog Scale scores 
4.7.4 Assumption 4. Correlation of predictors 
Collinearity begins to severely distort model estimation and subsequent 
prediction when Pearson’s r≥0.7.139 The majority of independent variables were not 
highly correlated. However, high correlations were present between smoking status and 
number of cigarettes smoked per day (30 days prior to baseline) (r=0.712), smoking 
status and time since quitting (r=-0.727), pack years and average number of cigarettes 
smoked per day (r=0.889) as well as FEV1 and FVC1 (r=0.729). Only one variable from 
each pairing was selected for potential inclusion; cigarettes smoked per day (last 30 
days), time since quitting, average number of cigarettes smoked per day (smoking 
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period) and FEV1 percent predicted. Without a specific measure of smoking status, 
former smokers are still represented in the regression model, embedded as values of 0 
in the variables cigarettes per day (30 days prior to baseline) with years since quitting 
smoking specified. Selected variables also exhibited greater univariate association with 
VAS scores. Average number of cigarettes smoked per day (smoking period) was 
selected for inclusion instead of pack-years. Peto (2012) noted that the effects of 
smoking should not be measured in pack-years and that a combination of smoking 
duration and average number of cigarettes per day is more scientifically helpful.155 As a 
sensitivity analysis, collinear variables were forced into the final model and in all cases 
were insignificant and had no effect on the R2 value. 
4.7.5 Assumption 5. Reducing measurement error 
 To ensure accuracy of measurements qualified research assistants administered 
study questionnaires to all participants with appropriate tools when necessary. Errors in 
memory may have been present among variables measuring historical exposures, such 
as smoking duration. Additionally, participants may be inclined to under- or over-report 
various measurements for reasons of social desirability, such as number of cigarettes 
consumed within the previous 30 days or level of educational attainment.156  
 Distributions of all continuous variables are available in Table 2. Outlying 
observations were identified by identifying observations which exceeded three standard 
deviations from the mean.156 Based on previous research, outlying observations were 
within a reasonable range of values and not representative of erroneous data. To ensure 
data naturality and interpretability, truncation or transformation was not completed as 
part of primary analysis.145 As a sensitivity analysis, continuous variables were 
transformed to reduce the effect of outliers and also replaced their original in the final 
regression model.145,157 In all cases, R2 decreased and interpretation of the associations 
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between independent variables and VAS score did not change. The proportion of 
outliers for all continuous variables did not exceed reasonable limits, 
√𝑁
𝑁
≅ 1.9%.158 
4.7.6 Assumption 6. Homoscedasticity 
 
This assumption requires that error term in the dependent variable be consistent 
across the ranges of values of predictor variables. A plot of residuals against fitted 
values of VAS score reveals a relatively equally random distribution around 0, indicating 
minimal differences in error terms of VAS score across the sample (Figure 12).  
 
Figure 12. Plot of residuals against fitted values of VAS score 
4.7.7 Background to the resultant models summary 
Assumptions of linear regression modelling were analyzed. The MFP selection 
procedure was utilized to identify non-linear associations in addition to linear 
associations. The assumption of normality in the dependent variable was violated. 
Assumption specific issues are not believed to impact results interpretability.  
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The assumptions of logistic regression; that the dependent variable be 
dichotomous and that each subgroup be mutually exclusive, were met. Greater than 50 
participants composed dependent variable subgroups, however, the categories of 
experiencing some problems and severe problems had to be combined to meet this 
criterion. Therefore, domain level data was analyzed using binary logistic regression 
rather than ordinal logistic regression.149 
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Chapter 5: Discussion and Conclusions 
This investigation aimed to examine the associations between socio-
demographic, medical history, exposure, morbidity and symptom variables, and health-
related quality of life (HRQoL). Data from the Pan Canadian Early Detection of Lung 
Cancer (PanCan) study, a large nationally representative sample of former and current 
smokers, were analyzed. General HRQoL was measured using the EuroQol visual 
analog scale (EQ VAS) and EuroQol 5 Dimension (EQ-5D) descriptive system. The 
multivariable fractional polynomial (MFP) selection procedure was combined with linear 
and logistic regression modelling to identify factors associated with HRQoL. 
5.1 Pertinent study findings 
 Multiple socio-demographic variables were found to have significant upstream 
and downstream associations with VAS scores as well as EQ-5D domains. A total of 15 
variables were significantly associated with VAS score, after adjusting for all factors. 
Results suggest that increased smoking exposure has negative upstream and 
downstream associations with HRQoL. The fully adjusted relationship between 
cigarettes smoked in the previous 30 days and VAS score, for participants who smoke 
one pack per day, suggests an association which is stronger than experiencing phlegm, 
hypercholesterolemia, pneumonia or arthritis. Furthermore, smoking duration, intensity 
of smoking throughout the smoking period, and time since quitting smoking are believed 
to have upstream associations with VAS score and domain level problems, which 
primarily appeared to be mediated through morbidities and symptoms.  
Of all morbidities, FEV1 percent predicted was most often associated with 
reduced HRQoL. Symptoms variables explained the greatest variation in VAS score and 
several symptoms increased odds of reporting some or severe problems in multiple EQ-
5D domains. Feeling fatigued or having a poor appetite had the greatest negative effect 
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on HRQoL when compared to gender, race/ethnicity and all other categorical symptoms 
or morbidities variables. Results of this study add to the limited number of population-
based investigations which simultaneously examine the relationships between socio-
demographic, medical history, exposure, morbidity and symptom variables and HRQoL. 
5.2 Questions #1 and #2. What socio-demographic, medical history, exposure, 
morbidity, and symptom variables are associated with a single estimator of overall 
HRQoL as measured by the EQ VAS in individuals with a heavy smoking history? What 
socio-demographic, medical history, exposure, morbidity, and symptom variables are 
associated with HRQoL domains (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) as measured by the EQ-5D?  
5.2.1 Socio-demographic and medical history variables 
Linear regression modelling suggests that socio-demographic and medical 
history variables may indirectly and directly affect HRQoL. All socio-demographic and 
medical history variables were significantly associated HRQoL in unadjusted models, 
with exception to familial cancer history. After full adjustment, gender, race/ethnicity, 
employment status and BMI had significant associations with HRQoL. 
Aging 
 Univariate analysis shows that older participants report higher VAS scores than 
younger participants. Increase in VAS score levels off at approximately 70 years of age. 
Lower quality of life scores amongst younger participants are thought to be due to 
increased smoking exposure among younger participants. Furthermore, participants 
below the median age, 80, report approximately one more symptom than those above. 
Increased age was also significantly associated with increased likelihood of reporting 
some or severe problems in the domains of usual activities and mobility, and decreased 
risk of reporting problems with anxiety/depression. Similar to VAS score, these 
associations were no longer present in the fully adjusted model. It is important to note, 
potential participants with heaviest smoking exposure would not have survived as long 
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as those with less exposure. This may give the appearance that older participants have 
improved HRQoL when it may be that those with lowest HRQoL and greatest smoking 
exposure were excluded from analysis. 
 The insignificance of age in all fully adjusted models and bootstrap analysis 
indicates that changes in VAS score or dimensional ratings as one ages are due to 
changes in other socio-demographic, medical history, smoking or alcohol exposures, or 
changes of morbidities and symptoms diagnosed. Multiple population based studies 
report a decline in HRQoL throughout the aging process.29,32 This generally holds true for 
smokers, however, several studies have concluded that HRQoL will increase, regardless 
of age, due to smoking cessation.159-161 
Gender 
Chi-square tests as well as unadjusted and adjusted regression models suggest 
no significant differences in VAS score by gender. However, a large proportion of 
bootstrap replications indicate that males consistently report lower VAS scores than 
females. Gender was also a significant factor in predicting HRQoL among EQ-5D 
domains. Males reporting lower HRQoL scores runs contrary to many studies which 
conclude that females tend to report lower HRQoL than males.83,89,162-164 It may be that 
important predictors of HRQoL, specifically those more common among females, were 
not included in our analysis. Mental health measures are of particular interest since 
logistic regression analysis reveals that females were almost twice as likely to report 
some or severe problems with depression and anxiety than males. A recent investigation 
conducted by Coste and colleagues (2014) note the effect of many significant predictors 
of SF-36 dimensions were mitigated or insignificant after adjusting for depression.165 
Other investigations recognize the importance of other socio-demographic 
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characteristics such as marital status, social relationships, or family income, which were 
not available for inclusion in regression analysis.83,163,166 
Race/ethnicity 
Results from the fully adjusted VAS regression model and bootstrap replications 
indicate non-Whites report lower VAS scores than White participants. However, 
race/ethnicity was insignificant when assessing all domain level logistic regression 
models. This suggests that race/ethnicity is an important predictor of HRQoL outside of 
the domains included in the EQ-5D. Previous research agrees that non-white 
populations report lower HRQoL than white populations.167 A review of multiple generic 
HRQoL instruments and race/ethnicity finds that non-white populations report poorer 
cognitive and social functioning, which are domains not measured by the EQ-5D.168 
Education 
Results indicate education to be an important upstream factor associated with 
VAS and HRQoL domains. PanCan participants with lower education reported greater 
exposure to harmful behaviours, such as smoking or consuming alcohol, in addition to 
increased total number of morbidities and symptoms. Maralani (2014) points out the 
advantages of being in a school environment in terms of reducing likelihood of smoking 
in later life. In addition to providing education and skills associated with reduced 
smoking, many schools enforce policies against smoking which are effective in reducing 
smoking later in life.169 Given that 88% of smokers begin smoking by age 18 and 99% by 
age 26, it is imperative that social policies encourage any level of further education. 
School policies must not only inform students of the harmful effects of smoking, but also 
aim to incorporate all students in activities. Even activities unrelated to physical health 
have shown to decrease likelihood of smoking in later life.57 Furthermore, higher 
education may result in increased salary, also associated with improved HRQoL.163 
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Employment status 
Compared to employed participants, retired individuals showed little HRQoL 
difference in univariate, and partially or fully adjusted linear regression analysis. Despite 
their unemployed job status, and likely lower income, unemployed participants reported 
greater weekly alcoholic drinks, smoked more cigarettes within the 30 days prior to 
baseline and more cigarettes per day throughout their smoking lifetime than employed 
participants. Unemployed participants consistently reported lower HRQoL than 
employed participants. This finding agrees with previous research which adds that 
unemployed participants report lower HRQoL in addition to more inadequate prevention 
behaviours.170 Extremera and Rey (2014), address the importance of cognitive emotion 
regulation strategies for those experiencing reduced HRQoL due to the social and 
financial stresses of being unemployed.171 
 Disabled participants or those on sick leave reported the lowest HRQoL of any 
subgroups measured. This pattern was also present in each of the EQ-5D dimensional 
measures. Even though several morbidities have been adjusted for, some physical or 
mental health conditions among the disabled or those on sick leave may be more 
impactful than the morbidities adjusted for in this study. 
Body mass index 
Unsurprisingly, a non-linear relationship between BMI and VAS score was 
identified after full adjustment. BMI was also a significantly associated with experiencing 
problems in multiple domains. Furthermore, hypercholesterolemia and myocardial 
infarction, both associated with decreased HRQoL, are more common among the 
overweight and obese.172,173 Overweight and obese smokers must be mindful of the 
harmful cardiovascular effects caused by smoking as it increases risk for serious 
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physical consequences in addition to further reduction in HRQoL. The importance of BMI 
to general and domain specific HRQoL supports findings from previous research.174-176 
5.2.2 Smoking and alcohol exposure 
As previously discussed, multiple studies have confirmed the importance of 
smoking status, duration and intensity to the development of chronic cardiovascular or 
pulmonary diseases. Average number of cigarettes smoked per day (previous 30 days) 
was the only smoking exposure variable independently associated with HRQoL. 
However, smoking duration, smoking intensity throughout smoking period and time since 
quitting smoking appear to be upstream factors associated with HRQoL. Fully adjusted 
regression analysis suggests that smoking 20 cigarettes per day may be approximately 
equal to a 3 point reduction in VAS score. Compared to smoking status, or average 
number of cigarettes consumed throughout a participant’s smoking period, cigarettes 
smoked per day in the 30 days prior to baseline is thought to be more meaningful to the 
variation in VAS scores because it more accurately describes individual participants’ 
current smoking status and intensity, and is less prone to measurement error than 
smoking intensity during the lifetime smoking duration. Fully aware that smoking may be 
damaging to their body, study participants may also report lower VAS scores simply 
because they associate present smoking intensity with poor HRQoL. Multiple studies 
agree with findings that increased recent daily tobacco exposure is associated with 
decreased HRQoL.19,21,166 It is also possible that important predictors relevant to HRQoL 
were not included in regression modelling. 
Pertaining to domain level data, smoking duration was the only smoking 
exposure variable associated with increased odds of experiencing any domain level 
problem, mobility. In their study of maintaining and restoring lower body mobility, Ostbye 
and colleagues (2002) discover that not smoking or smoking cessation is related to 
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improvements in mobility. Risk of experiencing mobility impairments was equal to that of 
never-smokers after 15 years of cessation.177 
Alcohol exposure 
Aside from cigarettes consumed within 30 days prior to baseline, weekly alcohol 
intake is the only exposure variable significantly associated with VAS in the univariate, 
partially adjusted and fully adjusted regression models. Weekly alcohol consumption 
was significantly associated with experiencing anxiety or depression, problems in 
completing usual activities and problems with self-care in univariate and partially 
adjusted logistic regression models. 
Non-parametric test of trend show a slight increase in VAS score among 
participants consuming 3 to 10 alcoholic drinks per week in comparison to those 
consuming less than 3 drinks per week. Participants consuming greater than 10 and 
greater than 20 alcoholic drinks per week showed successive decreases in VAS score. 
A review of potential health benefits arising from moderate alcohol consumption reports 
that all-cause mortality, cardiovascular disease, inflammation, the immune system and 
cancer, among other health conditions, may be positively affected by moderate alcohol 
intake.178 These results correspond with results from a recent meta-analysis which 
concludes that moderate alcohol intake is associated with a decrease in cardiovascular 
disease as well as all-cause mortality.179 However, pertaining to HRQoL, results from 
Strandberg (2004) 222, Byles (2006)159, and Volk (1997)160 indicate that moderate alcohol 
exposure offers little to no improvement over drinking less. Further research 
investigating effects of alcohol consumption and its potential indirect benefits on HRQoL 
by improving cardiovascular health are required.178 
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5.2.3 Morbidities 
Cardiovascular morbidities 
Despite all eight cardiovascular morbidities being associated with decreased 
HRQoL, only three, as well as BMI, were significantly associated with HRQoL in the fully 
adjusted MFP linear regression model; myocardial infarction, hypercholesterolemia and 
peripheral vascular disease (PVD). In addition to these variables, hypertension was 
included in slightly below 50% of bootstrap replications, indicating that it may be a 
meaningful predictor. Among domain level data, participants with hypertension, 
congestive heart failure or PVD reported higher odds of experiencing some or severe 
problems with mobility. Several studies agree with these conclusions.30,36,37  
It may be possible that cardiovascular morbidities not included in final regression 
models are still important HRQoL factors. Royston and Sauerbrei (2008) note that 
collinearity may affect a model even though a correlation coefficient between variables 
does not exceed r>0.7. In such a case, only one of two potentially important variables 
would be included in the final regression model or bootstrap replication. However, 
various sensitivity analyses which included different combinations of cardiovascular 
morbidities forced into the final regression model showed no improvement in R2 values. 
Pulmonary function and pulmonary morbidities 
Mean FEV1 percent predicted, of the PanCan sample was approximately 80%. 
Slightly greater than 10% of participants provided FEV1 percent predicted value greater 
than 100%. Therefore, approximately 10% of participants have FEV1 percent predicted 
greater than the reference population used to compute FEV1 percent predicted. These 
participants may be ‘healthy smokers’, those that smoke regularly but are unaffected by 
the common health effects of smoking. Non-parametric test of trend reveals that 
participants whose FEV1 is below 100%, have a significantly longer smoking history, 
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greater number of average cigarettes smoked per day throughout the smoking period of 
their lifetime, and significantly more cigarettes smoked per day within the 30 days prior 
to baseline, than those above 100%. These findings agree with data from longitudinal 
studies which have linked smoking to quicker declines in FEV1 percent predicted.
182-185 
PanCan results indicate that FEV1 percent predicted is an important predictor of 
VAS score and multiple domain outcomes. However, FEV1 percent predicted or 
pulmonary function variables are seldom analyzed in population samples. These results 
warrant further examination of pulmonary function variables among population samples, 
especially those including smokers. Multiple studies agree that FEV1 percent predicted 
and other pulmonary function variables significantly predict HRQoL.186-188 
A non-linear relationship was present in the fully adjusted regression model as 
well as over 60% of bootstrap replications. Researchers should be sure to adapt 
analysis involving FEV1 and HRQoL to handle non-linearity. 
Other pulmonary morbidities were rarely associated with VAS score or domain 
level outcomes in the presence of other covariates. However, pulmonary fibrosis was 
included among 58.2% of bootstrap replications, identifying it as a potentially important 
variable. As a population study, rather than clinical, prevalence and severity of chronic 
conditions were low. Therefore, some morbidities anticipated to be meaningful were not 
statistically significant. It is expected that pulmonary fibrosis is importantly associated 
with decreased HRQoL, but that the low number of participants with pulmonary fibrosis, 
3 individuals, did not provide sufficient study power. Previous research published by 
Tomioka and colleagues agrees that pulmonary fibrosis is a significant predictor of 
HRQoL.189 
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Other morbidities 
Arthritis is the only ‘other morbidity’ significantly associated with VAS score after 
full adjustment. Arthritis sufferers were also more likely to report problems with mobility, 
usual activities and pain or discomfort. Ibn Yacoub and colleagues (2012) agree, 
discovering that arthritis sufferers reported significantly lower HRQoL in all domains of 
the SF-36 and EQ VAS compared to the general population.190 
Results from this thesis confirm findings from previous population based 
investigations and clinical studies, adding that the population of former and current 
smokers at elevated risk of developing lung cancer is also affected. Furthermore, this 
investigation adds that factors significantly associated with HRQoL are significant in the 
presence of other socio-demographic, exposure, symptom, and morbidity factors not 
commonly simultaneously included in previous studies. Additionally, symptoms factors 
and pulmonary function measures, such as FEV1 percent predicted, were found to be 
highly significant with VAS and domain level HRQoL measurements. Inclusion of these 
variables, which are rarely incorporated in HRQoL analysis, should be considered. 
5.2.4 Symptoms 
Of all variable groups, symptoms variables explained the greatest variation in 
VAS score. Former smokers reported approximately one fewer symptom than current 
smokers. After full adjustment, five symptoms were highly associated with VAS score 
and four were included in over 90% of bootstrap replications. Multiple symptoms were 
significantly associated with each of the EQ-5D domains, in particular, dyspnea, fatigue 
and poor appetite. In their investigation of symptom distress in COPD patients 
Blinderman and colleagues (2009) discover dyspnea, chest pain, poor appetite and 
fatigue to be among the most frequently experienced, severe or stressful symptoms.180 
Furthermore, poor quality of life was associated with higher symptom distress. 
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Investigations by Voll-Aanerud (2008) and (2010), of participants diagnosed with COPD 
agree with our findings, concluding that dyspnea, chest pain and phlegm production 
significantly affect HRQoL.33,35 Leander and colleagues (2009) agree, adding that 
symptoms are common among individuals without diagnosed morbidities.181 Of PanCan 
participants with no respiratory morbidities, almost 80% reported experiencing one or 
more symptoms. 
5.3 How does the VAS score of PanCan participants compare to other samples in 
Canada and elsewhere?  
Compared to other Canadian and international populations, PanCan participants 
generally reported lower VAS scores than general populations and similar scores 
compared to smokers. In a comparison of the EQ-5D to the SF-12, questionnaires from 
1,490 residents of Calgary, Alberta were analyzed. Mean VAS score of participants aged 
55 to 64, 78.8, was greater than PanCan participants of the same age group from 
Alberta, 74.9. This is unexpected considering the smoking history of PanCan 
participants. However, participants aged 65 to 74 reported similar mean VAS scores 
(Alberta sample: mean=76.0 vs. PanCan sample: mean=76.6).125  
Luo and colleagues examined data from a general population sample. Americans 
aged 45 to 64 reported a mean VAS score of 84.127 A similar PanCan age group, 50 to 
65 years old, had a mean VAS score of 75.9. In Luo’s sample, participants aged ≥65, 
mean VAS=81 also reported greater mean VAS score than the same age group of the 
PanCan, mean VAS=77.9. The closing gap in VAS score between samples may be the 
result of older PanCan participants smoking less intensely than younger participants, 
thereby increasing their HRQoL. 
Another American general population sample with mean age of 45 also reported 
greater mean VAS score, 84.32, than the PanCan sample, 76.8.151 In comparison to a 
United Kingdom sample, the working, 87.5, and unemployed, 82.0, both reported greater 
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mean VAS scores than PanCan participants (working=78.0, unemployed=66.9).152 
Current smokers in the United Kingdom sample also reported greater VAS scores than 
PanCan current smokers (mean United Kingdom sample=80.4 vs. mean PanCan=75.6).  
5.3 Study limitations 
5.3.1 Lack of longitudinal data 
Baseline cross sectional data from the PanCan was analyzed in this 
investigation. Therefore, conclusions are associations between variables and may not 
represent causal relationships. Any potential causal relationships between socio-
demographics, smoking exposure, morbidities and symptoms, and HRQoL require 
analysis of longitudinal data. 
5.3.2 Normality assumption 
The assumption of linear regression modelling that the dependent variable be 
normally distributed was modestly violated. Even though validating this assumption may 
not be important to samples as large as the PanCan, a normal distribution is preferred. 
Bootstrap validation was completed in order to provide added confidence to the 
conclusions based upon linear regression modelling. Transformations of the dependent 
VAS variable were also assessed. A cubed transformation was deemed to most closely 
resemble a normal distribution, however, regression results indicated the linear 
regression model with the original VAS function (R2=0.284) explained greater variation in 
VAS score than the cubed transformation (R2=0.251). 
5.3.3 Predominantly white sample 
The PanCan sample is approximately 97% white. Furthermore, the remaining 3% 
of participants (N=66) were divided between 6 different race/ethnicities. In the interests 
of study conclusions it would be best to avoid aggregating distinct race/ethnicities into a 
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single category. This would avoid potential misclassification bias and also makes 
findings relevant to wider audiences. 
5.3.4 Few participants experiencing severe problems among domain level data 
Ordinal logistic regression was planned for analysis of EQ-5D domain level data. 
This would allow for individuals experiencing some and severe problems to be compared 
with those experiencing no problems. However, few participants report severe problems. 
As noted in the EQ-5D-3L user guide, this is a common occurrence among population 
studies where participants are less likely to report severe problems compared to clinical 
investigations. Participants reporting some or severe problems were combined into a 
single category, as per EuroQol’s recommendation.124  
5.3.5 Unaccounted independent predictors 
Some variables which have been shown to be important predictors of HRQoL in 
previous investigations were unavailable for inclusion. Particularly, marriage status, 
number of children, household income, mental health status and social relationships, 
including discrimination, are measures of interest. 
5.4 Study strengths 
5.4.1 Study sample and variation of independent predictors 
The PanCan is a nationally representative sample of 2,537 former and current 
smokers who have provided a wide array of data describing their socio-economic status, 
current and previous smoking exposure, symptoms, morbidities and pulmonary function. 
Data was carefully collected through in-person interview. Many population-based studies 
investigating factors associated with HRQoL do not extend analysis to include measures 
of exposures, symptoms, morbidities and pulmonary function. Furthermore, smoking 
exposure is commonly limited to a single variable, often measured categorically, such as 
smoking duration, pack-years or average number of cigarettes smoked per day 
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throughout smoking duration. Studies which incorporate these detailed independent 
variables often focus on disease subgroups recruited from clinical settings. 
5.4.2 Use of continuous independent variables as opposed to using cut points  
Variables such as BMI, average number of cigarettes consumed per day (last 30 
days) and FEV1 percent predicted are often examined categorically rather than as a 
continuous function.12 Analyzing continuous variables using cut points may allow for 
easy interpretation or comparison but the amount of information in analysis decreases, 
producing results which may not accurately describe true effects. Non-linear 
relationships may exist between independent and dependent variables. Observing 
trends in categorical data may suggest a non-linear relationship but plotting and 
reviewing continuous data allows researchers to clearly observe linear or non-linear 
relationships between variables. The MFP selection procedure used to identify non-
linear relationships is relatively new and should continue to be implemented in further 
investigations. 
5.4.3 Internal validation of independent predictors of VAS score with bootstrapping 
Regardless of the recommendation to internally validate regression models, 
bootstrap analyses are often not completed. Analysis of bootstrap inclusion frequencies 
enables the assessment of a variable’s importance to the regression model. Some 
variables which were insignificant or borderline significant in the full regression model 
proved to be important predictors of VAS score when analyzing bootstrap results. In 
addition to whether a variable is important to a regression model, the linearity, or lack 
thereof, can be assessed. For non-linear predictors, exponential frequencies can be 
analyzed to determine the most accurate and parsimonious function to describe the 
relationship in question. This was particularly useful when analyzing the relationship 
between FEV1 and VAS score. 
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5.5 Future Research 
Along with incorporating study strengths, future research can continue to build 
upon study results in several ways. Analysis of longitudinal data will allow researchers to 
observe temporal associations which are necessary for further and overall 
understanding. To strengthen causal conclusions, researchers should also investigate 
the direct relationships between socio-demographics, smoking and alcohol exposures, 
morbidities and symptoms. In addition to the variety of independent variables, measures 
of income, marital status, number of children, social health, mental health and a more 
racially/ethnically diverse sample should also be analyzed. Stratification was beyond the 
scope of this project. However, comparing differences within significant independent 
variable subgroups is a logical proceeding step. 
5.6 Clinical and public health implications of the study findings 
Policy makers should make known the potential for increasing HRQoL through 
smoking cessation. As preventative measures, continued effort must be made by policy 
makers to ensure that students stay in school, are properly educated from a young age 
on the effects of smoking as well as smoking cessation, and that school policies 
encourage student involvement in various activities as well as smoke free environments 
for students and teachers. Healthcare practitioners need to be sensitive to their patient’s 
demographic, recognizing that minorities and the unemployed are more likely to report 
poor HRQoL than their counterparts. Policy makers in all levels of government should 
continue to focus on reducing unemployment, not only to improve the economy but also 
individual well-being. Furthermore, more employers should promote reducing harmful 
behaviours among employees. This is also beneficial to employers as research indicates 
current smokers add to employer healthcare costs and are also less productive than 
non-smokers.191 
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 In addition to improving general health, smoking reduction campaigns need to 
make smokers aware that their general day-to-day HRQoL is also likely to improve if 
they are able to quit or reduce smoking. Immediate benefits in HRQoL may arise from 
reducing the number of daily cigarettes consumed and from an eventual reduction in 
morbidities and symptoms caused by smoking. Caregivers should tailor treatments of 
current and former smokers to focus on the symptoms (dyspnea, phlegm, chest pain, 
poor appetite and fatigue) and morbidities (hypercholesterolemia, myocardial infarction, 
arthritis and pulmonary function) most strongly associated with reduced HRQoL. Even 
when no morbidities have been diagnosed, symptom experiencing individuals and their 
medical caregivers should seek to treat symptoms in order to improve HRQoL. 
5.7 Conclusion  
Multiple socio-demographic, exposure, morbidity and symptom variables are 
shown to have significant associations with HRQoL. More specifically, being non-white, 
unemployed, disabled or on sick leave, and having non-normal BMI have significant 
upstream associations with HRQoL. Older age and lower educational attainment also 
exhibit negative upstream associations with HRQoL.  
Improving educational and employment opportunities, promoting normal BMI and 
preventing or reducing smoking and excess alcohol consumption are expected to lessen 
consequent morbidities and symptoms, thus broadly improving HRQoL. 
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Appendices 
 
Appendix 1a. Bootstrap inclusion fractions for all variables included in regression 
modelling, 1000 replications, N=2397 
 
 1
st
 Polynomial 
 
2
nd
 polynomial 
 
Independent variable % 
Inclusion 
Exponential 
Mean 
Mean β % 
Inclusion 
Exponential 
Mean 
Mean β 
Age 30.2 1.01 -114 6.3 2.13 247 
Gender  
(male vs. female) 
77.7 1 -1.96    
Race/ethnicity 
 (non-white vs. white) 
60.2 1 -4.69    
Education 8.8 -1.07 -5.17 2.8 -.589 12.2 
BMI 99.9 -.365 -39.2 52.2 -1.92 225 
Retired 100.0 1 -1.67    
Unemployed 100.0 1 -6.56    
Disabled 100.0 1 -11.2    
Sick leave 100.0 1 -14.4    
Other 100.0 1 .645    
Familial cancer 
history 
44.2 1 1.56    
Cigarettes per day 
(smoking period) 
30.5 .033 -.149 7.7 1.14 1.06 
Cigarettes per day 
(last 30 days) 
73.6 .995 -.778 11.0 1.3 .289 
Smoking duration 40.4 2.06 -.356 22.9 3.0 -.345 
Time since quit 30.1 .806 2.7 2.9 -.431 .392 
Average alcohol per 
week 
65.4 .696 -3.68 4.4 -.523 1.1 
Average marijuana 
use 
17.8 .183 -4.27 7.8 1.1 -5.24 
Dyspnea 100 1 -3.1    
Cough 14.4 1 1.45    
Phlegm 55.6 1 -1.69    
Hemoptysis 22.9 1 4.79    
Hoarseness 49.4 1 -1.76    
Wheeze 32.2 1 -1.67    
Chest pain 91.6 1 -2.55    
Poor appetite 96.6 1 -4.4    
Fatigued 100.0 1 -5.77    
Stroke 9.2 1 -2.67    
CHD 31.1 1 -3.31    
Angina 10.4 1 -2.37    
Myocardial infarction 51.7 1 -3.69    
Hypercholesterolemia 46.8 1 -1.55    
Hypertension 44.9 1 -1.58    
Congestive heart 
failure 
27.9 1 7.69    
PVD 46.3 1 -3.87    
Asthma 22.2 1 -2.27    
COPD 7.9 1 -.619    
Pulmonary fibrosis 58.2 1 -26.8    
Pneumonia 44.5 1 -1.6    
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Appendix 1b. Bootstrap inclusion fractions for all variables included in regression 
modelling, 1000 replications, N=2397 
 1
st
 Polynomial 
 
2
nd
 polynomial 
 
Independent variable % 
Inclusion 
Exponential 
Mean 
Mean β % 
Inclusion 
Exponential 
Mean 
Mean β 
Liver disease 7.2 1 -.645    
Kidney disease 7.3 1 -.222    
Osteoporosis 27.7 1 -2.02    
Arthritis 92.0 1 -1.97    
Weight loss 9.4 1 1.5    
Allergy 6.4 1 -1.36    
Diabetes 27.0 1 -2.39    
Anemia 10.0 1 -1.89    
Blood disease 25.8 1 -4.77    
FEV1,
 
% predicted 99.5 -.492 .652 2.8 2.86 -3.51 
Abbreviations: β, beta-coefficient; BMI, Body Mass Index; CHD, coronary heart disease; PVD, peripheral 
vascular disease; COPD, Chronic obstructive pulmonary disease; FEV1, Forced Expiratory Volume in one 
second 
 
Appendix 2. Frequency of first and second polynomial exponent combinations for BMI 
and VAS score, 1000 bootstrap replications 
 
  2
nd
 polynomial exponent 
1
st
 polynomial exponent -2 -1 -0.5 0 0.5 2 3 Insignificant 
-2 500 11 2 4 1 2 2 0 
1 0 0 0 0 0 0 0 376 
3 0 0 0 0 0 0 0 101 
Insignificant 0 0 0 0 0 0 0 1 
 
Appendix 3. Frequency of first and second polynomial exponent combinations for daily 
cigarettes smoked in last 30 days and VAS score, 1000 bootstrap replications 
 
 2
nd
 polynomial exponent 
 
1
st
 polynomial exponent -1 -0.5 0 0.5 1 2 3 Insignificant 
-2 1 0 2 0 2 0 0 0 
-1 4 9 3 1 0 0 0 0 
-0.5 0 9 6 0 0 0 0 2 
0 0 0 8 5 0 0 0 3 
0.5 0 0 0 1 0 0 1 1 
1 0 0 0 0 0 6 1 607 
2 0 0 0 0 0 20 16 6 
3 0 0 0 0 0 0 15 8 
Insignificant 0 0 0 0 0 0 0 264 
 
 
 
 
 
 
 
 
 
 
117 
 
Appendix 4. Frequency of first and second polynomial exponent combinations for weekly 
alcohol exposure and VAS score, 1000 bootstrap replications 
 
 2
nd
 polynomial exponent 
 
1
st
 polynomial exponent -2 -1 -0.5 0 1 2 3 Insignificant 
-2 17 9 4 3 0 0 0 3 
-1 0 1 0 0 0 0 0 3 
-0.5 0 0 0 0 0 1 0 6 
0 0 0 0 0 0 0 0 54 
0.5 0 0 0 0 0 0 0 55 
1 0 0 0 0 2 1 0 489 
2 0 0 0 0 0 1 2 0 
3 0 0 0 0 0 0 3 0 
Insignificant 0 0 0 0 0 0 0 347 
 
 
Appendix 5. Frequency of first and second polynomial exponent combinations for FEV1, 
percent predicted and VAS score, 1000 bootstrap replications 
 
 2
nd
 polynomial exponent 
 
1
st
 polynomial exponent 1 2 3 Insignificant 
-2 0 0 22 229 
-1 0 0 0 342 
-0.5 0 0 0 35 
0 1 0 0 0 
1 0 0 1 361 
2 0 2 0 0 
3 0 0 2 0 
Insignificant 0 0 0 5 
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Appendix 6. Transformations of VAS score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
